



# Purinergic modulation of the immune response to infections

Natalia Eberhardt<sup>1,2</sup> · Gastón Bergero<sup>1</sup> · Yanina L. Mazzocco Mariotta<sup>1</sup> · M. Pilar Aoki<sup>1,3</sup>

Received: 27 September 2021 / Accepted: 17 December 2021 / Published online: 8 January 2022

© The Author(s), under exclusive licence to Springer Nature B.V. 2022

## Abstract

Infectious diseases are caused by the invasion of pathogenic microorganisms such as fungi, bacteria, viruses, and parasites. After infection, disease progression relies on the complex interplay between the host immune response and the microorganism evasion strategies. The host's survival depends on its ability to mount an efficient protective anti-microbial response to accomplish pathogen clearance while simultaneously preventing tissue injury by keeping under control the excessive inflammatory process. The purinergic system has the dual function of regulating the immune response and triggering effector antimicrobial mechanisms. This review provides an overview of the current knowledge of the modulation of innate and adaptive immunity driven by the purinergic system during parasitic, bacterial and viral infections.

**Keywords** Purinergic system · Infectious diseases · Immune response · ATP · Adenosine

## Abbreviations

ADA	Adenosine deaminase	CLP	Cecal ligation and puncture
ADO	Adenosine	CMV	Cytomegalovirus
ADORA	Adenosine receptors	CRS	Cytokines release syndrome
ADP	Adenosine diphosphate	DENV	Dengue virus
AIDS	Acquired immunodeficiency syndrome	EBV	Epstein-Barr virus
AMP	Adenosine monophosphate	E-NTPDases	Ectonucleoside triphosphate diphosphohydrolases
ART	Antiretroviral therapies	HBV	Hepatitis B virus
ATP	Adenosine triphosphate	HCC	Hepatocellular carcinoma
BM	Bone marrow	HCV	Hepatitis C virus
CK-MB	Creatine kinase-myocardial band	HDV	Hepatitis D virus
		HIV	Human immunodeficiency virus
		HPV	Human papillomavirus
		IECs	Intestinal epithelial cells
		IFN	Interferon
		IL	Interleukin
		iNOS	Inducible nitric oxide synthase
		KO	Knock-out
		MDSCs	Myeloid-derived suppressor cells
		NECA	5'-N-ethylcarboxamide adenosine
		NETs	Neutrophil extracellular traps
		NO	Nitric oxide
		PAMPs	Pathogen-associated molecular patterns
		Tfh	T follicular helper cells
		TLR	Toll-like receptors
		TNF	Tumor necrosis factor
		Tr1	Type-1 regulatory T cells
		Treg	Regulatory T cell

✉ M. Pilar Aoki  
pilar.aoki@unc.edu.ar

Natalia Eberhardt  
natalia.eberhardt@nyulangone.org; neberhardt@unc.edu.ar

Gastón Bergero  
gbergero@unc.edu.ar

Yanina L. Mazzocco Mariotta  
ymazzocco@unc.edu.ar

<sup>1</sup> Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET) - Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina

<sup>2</sup> Present Address: Department of Medicine, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, USA

<sup>3</sup> Haya de La Torre and Medina Allende, Ciudad Universitaria, CP 5000 Córdoba, Argentina


VL Visceral leishmaniasis  
WT Wild-type

## Introduction

The immune response is a biological process to protect the host from infections. A healthy immune system can recognize and differentiate self-antigens and antigens belonging to microorganisms such as parasites, fungi, viruses and bacteria. As such, immunity pursues pathogen clearance and preserves tissue homeostasis through a wide range of complex networks that involve cellular and humoral components with regulatory feedback systems [1]. A variety of inflammatory and suppressive responses are generated following infection or injury to restore the homeostatic conditions. The host exerts intrinsic control between both responses to achieve pathogen elimination while simultaneously preventing collateral damage.

The purinergic system has the dual function of modulating the host immune response and triggering effector mechanisms [2–4]. Adenosine triphosphate (ATP), adenosine (ADO) and other purine metabolites are the major representative mediators of purinergic signaling cascades (Fig. 1) [5]. The release of intracellular ATP in response to hypoxic or inflamed conditions by intact, activated or dying cells is the first step of purinergic signaling [6]. Extracellular ATP can activate and initiate a purinergic signaling cascade through purinergic receptors, a concept introduced by Geoffrey Burnstock in the early 1970 [7]. Extracellular ATP triggers multiple immune

effector functions to inhibit infections and is primarily a pro-inflammatory metabolite [8], which can act at both paracrine and autocrine level activating two types of P2 receptors [9]. P2X receptors are plasma membrane channels that mediate influx or efflux of various cations, such as  $\text{Ca}^{+2}$ . P2Y are G-protein-coupled receptors that modulate signaling events of secondary messengers [10]. The life span of extracellular ATP is determined by purinergic ectoenzymes that coordinate a two-step enzymatic process of ATP hydrolysis into the potent anti-inflammatory ADO. The family of ectonucleoside triphosphate diphosphohydrolases (*E-NTPDases*), the largest family of ectonucleotidases consisting of eight E-NTPDases, hydrolyze nucleotide triphosphates (e.g., ATP) and diphosphates (e.g., adenosine diphosphate ADP) to generate nucleotide monophosphates (e.g., AMP). The most studied is the ENTPD1, also known as ecto-apyrase CD39 [11]. The second and limiting enzymatic step for ADO production involves converting AMP mediated by 5'-ectonucleotidase (*NT5E*), commonly known as CD73. Extracellular ADO exerts a central role in restricting tissue inflammation, as it is considered a retaliatory metabolite that inhibits ATP-driven pro-inflammatory effects due to its recognition by P1 receptors [12]. There are 4 types of purinergic G-coupled receptors ADO receptors (ADORA): ADORA1, ADORA2a, ADORA2b and ADORA3, which bind ADO with different affinity and exert various functions. It should be noted that ADO half-life in the extracellular compartment is extremely short, as it is metabolized by adenosine deaminase (ADA) between 15 seconds to a couple of minutes, depending on the host [13].



**Fig. 1** Components of the purinergic signaling pathway. Stimulation of specific surface immune cell receptors that recognize pathogens, antigens, cytokines or chemokines triggers the release of ATP through connexin or pannexin hemichannels. ATP in the extracellular space can stimulate the P2X or P2Y receptors to trigger an inflammatory response. The ecto-apyrase (CD39) catalyzes the hydrolysis

of ATP to ADP/AMP, and consecutively, the enzyme 5'-ectonucleotidase (CD73) catalyzes the limiting step of conversion to adenosine (ADO), which is the ligand for P1 receptors promoting anti-inflammatory responses. ADO can be removed by nucleoside transporters, which facilitates its cellular absorption, or by adenosine deaminase (ADA), which converts ADO to inosine

Although dampening inflammation is beneficial for preventing tissue damage ensuring host survival, it may also be detrimental for pathogen clearance after infection. The failure in the fine control of the immune response balance can alter pro-inflammatory/regulatory microenvironments, which eventually lead to pathophysiological conditions, such as chronic infectious diseases. In this regard, protective immune responses in some instances are the countermeasures that prevent disease, but not necessarily infection. Besides immune cells, several pathogens also utilize or possess purinergic machinery to foster their persistence or disrupt the host immune response.

## Purinergic modulation of immune response

Purinergic signaling involves various mechanisms used by innate and adaptive immune cells to modulate their functions and adapt to local microenvironment [14]. During inflammatory conditions, the purinergic signaling pathways are activated to initiate immune cell chemotaxis toward inflamed tissue and fine-tuned control local inflammation. Initially, ATP release to the extracellular environment is mediated by pannexin or connexin hemichannels to regulate cell functions in an autocrine or paracrine manner [8]. The first cell to arrive at the inflammation site is the neutrophil, which employ an extracellular ATP-dependent mechanism to generate a chemotactic gradient and orientate its migration [15, 16]. Remarkably, the purinergic system regulates many effector functions of neutrophils, such as phagocytosis, oxidative burst, degranulation and neutrophil extracellular traps (NETs) formation [17]. After its death, apoptotic neutrophils release ATP to stimulate mononuclear phagocytic cell influx and promote engulfment and clearance functions [18]. The local microenvironment composed by ATP and the consequent metabolization to ADO by CD39 and CD73 ectoenzymes influence host–pathogen interaction by metabolic reprogramming of the innate and adaptive immune cells [19, 20]. Among myeloid cells, macrophages are the most studied cells in terms of phenotype and function modified by the purinergic system [21]. Several studies reported that ADO can reprogram monocyte and macrophages from a microbicidal and pro-inflammatory profile (classically activated—M1-like phenotype) to an alternatively activated and anti-inflammatory (M2-like) phenotype via ADORA receptors [22]. Macrophages have high plasticity capacity and can undergo profound metabolic modifications when recognizing pathogen-associated molecular patterns (PAMPs) mediated by Toll-like receptors (TLR)-stimulation. Indeed, macrophages induce the production of ATP and rapid extracellular degradation to control their activation state in an autoregulatory mechanism [23]. CD39 deficiency in macrophages promotes a sustained inflammatory activation state

and inhibits the switch to an immunosuppressive phenotype [24]. ADO stimuli of ADORA2a and ADORA2b receptors in macrophages increase the expression of M2 macrophage markers and diminish the expression of inflammatory genes [25, 26]. In addition, ADO has been reported to induce the production of anti-inflammatory cytokines such as IL-10 and VEGF and suppress the production of pro-inflammatory cytokines (TNF- $\alpha$  and IL-6) by macrophage [27]. ADORA2b-inhibited and IFN- $\gamma$ -treated macrophages extend their microbicidal and pro-inflammatory activities with increased IL-12 and TNF- $\alpha$  production in response to TLR stimulation [28].

Regarding adaptive immunity, the purinergic system has been reported as a modulator of the induction of different T helper profiles. T cell antigen receptor (TCR) ligation initiates T cell activation by increasing cytosolic calcium and the release of ATP via pannexin-1 mechanism. Extracellular ATP acts in an autocrine manner via P2X receptors to induce IL-2 production and cell proliferation. The absence of this purinergic pathway leads to T cell anergy with increased expression of anergy-associated genes 2 and 3 (*Erg2* and *Erg3*) [29]. In line with this, ATP-dependent activation of P2X7R inhibits suppressive functions of T regulatory (Treg) cells, inducing the Th17 differentiation [30]. Furthermore, P2X7R plays a role in generating long-lived memory CD8 + T cells, regulating their mitochondrial fitness and promoting the differentiation and survival of resident memory subsets via TGF- $\beta$  signaling [31, 32]. On the other hand, ADORA2a receptor signal inhibits Th1 cell generation and IFN- $\gamma$  production, triggering the induction of FoxP3 + Treg cell subset and the production of TGF- $\beta$  [33, 34]. ATP catabolism and generation of retaliatory metabolite ADO is a typical suppression mechanism of regulatory cells involving Treg, type-1 regulatory (Tr1) T cells and myeloid-derived suppressor cells (MDSCs) [35, 36]. These regulatory cells express CD39 and CD73 to abrogate ATP-related effects and enable the inhibitory properties [37–40].

## Relevance of the purinergic immune modulation in infectious diseases

The purinergic system has acquired a fundamental role in cellular and tissue microenvironment modulation upon damage to promote system regeneration and homeostasis [2, 3]. Remarkably, immune cell regulation mediated by purinergic signaling pathways has taken great therapeutic relevance in carcinogenic and inflammatory processes. The role of purinergic signaling in the immunomodulation in these contexts was reviewed elsewhere [41, 42]. Several recent studies suggest that a precisely orchestrated purinergic mechanism defines effector functions on immune cells and, thus, the result of host–microbe interaction [3, 11, 14,

43, 44]. However, a clear understanding of its relevance in the pathogenesis of infectious diseases and the possible therapeutic approaches still requires future research. Here, we focused on understanding the regulation of immune cell effector functions driven by purinergic signaling in the context of parasitic, viral and bacterial infections and their effects on pathogen clearance. This review aims to comprehensively summarize the current literature regarding the purinergic modulation of the immune response to pathogens and the impact on the development and progression of infectious diseases.

## Parasitic infections

Leishmaniasis comprises a wide range of diseases caused by the infection with the protozoan parasite *Leishmania* transmitted by the bite of infected female phlebotomine sandflies. Infection clinical presentation may be asymptomatic or may manifest as cutaneous or muco-cutaneous disease, which if left untreated may result in disfiguring scars; or the visceral form that may be lethal if untreated. The lack of a vaccine against human leishmaniasis and the diverse response to treatment make this disease a significant worldwide health problem. Several studies suggest a potential contribution of purinergic nucleotidases in *Leishmania* immune responses [45]. Indeed, *Leishmania* parasites augment ectonucleotidases activity to increase ADO production and consequently establish a chronic infection through purinergic immunoregulatory mechanisms [46]. Patients with visceral leishmaniasis (VL) present increased levels of ADA and ADO [47]. Increased ADO levels were further confirmed and associated with disease's pathogenicity, diminishing with the successful treatment. Moreover, the frequency of CD73 + CD39 + double-positive cells is augmented in VL active disease compared with treated VL patients and healthy controls [48]. Additionally, circulating monocytes exhibit upregulated levels of ADORA2b receptor, which shows direct association with parasite load. ADO signaling in *L. donovani*-infected monocytes inhibits IL-10 production and nitric oxide (NO) release, promoting immune downmodulation and parasite survival [49]. Besides, bone marrow (BM) from VL patients shows increased ADA levels compared to the non-infected BM, which inversely correlated with the local parasite load [50]. Recently, it was demonstrated that murine macrophages release ATP and increase CD39 and CD73 expression upon in vitro *L. donovani* infection. Thus, the resulting extracellular ADO promotes an anti-inflammatory microenvironment crucial for parasite persistence through ADORA2a and ADORA2b signaling [51]. On the other hand, *L. infantum* parasites utilize ADORA2a signaling pathway to successfully colonize the host and promote parasite surveillance. Indeed, ADORA2a-deficient

mice present robust Th1 adaptive immune response in infected organs with augmented neutrophil infiltration and decreased Treg cells and IL-10 production. In accordance, infected ADORA2aKO mice show reduced parasite burdens in liver and spleen compared to infected wild-type (WT) mice [52]. Furthermore, after *L. amazonensis* infection, murine macrophages are significantly more sensitive to extracellular ATP-induced pore opening and show augmented P2X7R expression. ATP treatment inhibits parasite growth in an apoptosis-dependent mechanism [53]. Interestingly, *L. amazonensis* elimination mediated by P2X7R and LBT4 is dependent on non-canonical NLRP3 inflammasome and IL-1 $\beta$  signaling activation, as well as ROS production [54]. A crosstalk between P2Y2R and P2X7R is evidenced by the fact that both receptors cooperate to trigger a potent protective response against *L. amazonensis* infection [55]. However, Coutinho-Silva and colleagues proposed another protective role for P2X7R since infected P2X7R-deficient mice show increased IFN- $\gamma$  and reduced TGF- $\beta$  production suggesting that an exacerbated pro-inflammatory response could increase the susceptibility to infection. In fact, P2X7R abrogation results in increased *L. amazonensis* parasite load and lesion size [56]. Altogether, these studies suggest that purinergic signaling plays a critical role in host immune response and parasite interaction; however, the fine balance of those signals would determine the outcome of infectious diseases.

Notably, several reports established a close relationship between the E-NTPDase and ecto-5'-nucleotidase activities to the virulence in different species of *Leishmania* genus [57]. The virulent parasite *L. amazonensis* hydrolyzes higher amounts of purinergic nucleotides compared to other species. Addition of ADO at the time of infection results in augmented skin lesion size and parasite load. In the same line, ADORA2b receptor inhibition decreases injury size and parasitism. Thus, ADO immunomodulatory properties contribute to the establishment of *Leishmania* infections [58]. Previous studies reported that *L. amazonensis* employs ADORA2b receptor signaling to suppress dendritic cell activation as an evasion mechanism. Blockade of ADORA2b receptor by PSB1115 treatment in vivo reduces lesion size and tissue parasitism, as well as increases IFN- $\gamma$  levels [59].

Toxoplasmosis is caused by the infection with the protozoan parasite *Toxoplasma gondii* and is one of the most common human zoonoses, infecting about a third of the world's population. The disease is generally benign and often goes unnoticed in immunocompetent individuals; however, the infection also has health-threatening and fatal implications in immunocompromised individuals. In immunodeficiency conditions, reactivation of a latent infection might result in encephalitis, which is potentially fatal if not treated properly. Susceptibility to this infection is determined by the inability of the host immune response to control parasite replication.


*Toxoplasma gondii*-infected Wistar rats present increased E-NTPDase and E-ADA activities in circulating lymphocytes at early days post-infection, showing a positive correlation with the number of lymphocytes [60]. Likewise, the infection causes increment in the purine levels in the brain with the exception of inosine, which was diminished due to diminished ADA activity [61]. Treatment of *T. gondii*-infected Swiss mice with resveratrol, a non-flavonoid polyphenol, decreases ATP and AMP hydrolysis by NTPDase and CD73 and increases ADA activity in the cerebral cortex compared with non-treated infected groups [62]. Nevertheless, several studies assign a protective role to the purinergic ectoenzymes against *T. gondii* infection. CD73 genetic deficiency in mice infected with *T. gondii* increases their susceptibility to acute toxoplasmosis, with augmented neutrophils and T cell infiltration into the peritoneal cavity and increased levels of pro-inflammatory cytokines. Because of this, the ADO receptor agonist (NECA) treatment protects CD73-deficient mice against *T. gondii*-induced immunopathology [63]. In the same line, CD73-dependent ADO production and ADORA2a/2b activation protect the host from developing lethal pathology. Acute *T. gondii* infection induces the reduction of CD73+ cells in several infected tissues and increases immune-mediated pathology in the gastrointestinal tract and mucosa [64].

In contrast to the acute infection, during chronic toxoplasmosis CD73-generated ADO has a detrimental role because it is essential for *T. gondii* bradyzoite differentiation and cyst formation in the central nervous system. Indeed, CD73-deficient mice are more resistant to chronic infection and present reduced parasite burden in the brain compared to WT mice [65]. Accordingly, it is of ultimate importance to consider the radical differences between host immune response during the acute or chronic phases of the infection to therapeutically promote parasite eradication. Alternatively, the P2X7R was widely studied as a host mechanism of resistance to infection. P2X7R deficiency in oral *T. gondii*-infected mice leads to higher susceptibility to cerebral toxoplasmosis, with an increased number of cysts, less inflammatory infiltrates and reduced pro-inflammatory cytokine levels [66]. In this sense, it was demonstrated that P2X7R activation inhibits *T. gondii* replication in macrophages by canonical NLRP3 inflammasome activation, which in turn produced IL-1 $\beta$  leading to increased mitochondrial ROS production [67]. These findings are consistent with other reports confirming that P2X7R activation in macrophages mediates the killing of tachyzoites [68, 69]. Furthermore, P2X7R signaling in epithelial cells mediates CCL5 chemokine responses to promote the recruitment of CD11c+ CD103+ dendritic cell in the intestinal epithelium promoting the initiation of the immune response [70]. Besides, activation of P2Y receptors in infected macrophages mediated by UTP and UDP induces early egress of tachyzoites and these parasites have

reduced infectivity in subsequent infections [71]. The role of purinergic signaling in *T. gondii* infection was recently summarized in [72].

Chagas disease is caused by the infection with the protozoan parasite *Trypanosoma cruzi*. About 6 million people are estimated to be infected worldwide, mostly in Latin America. Chronic cardiomyopathy represents the most frequent and serious complication of this infectious disease. To date, there is no effective chemotherapy or prophylactic vaccine. Our group has reported that Chagas patients in the indeterminate stage show diminished frequencies of circulating CD39+ and CD73+ lymphocytes and increased plasma ATP levels [73]. In line with this, peripheral monocytes exhibit long-lasting functional phenotypic changes evidenced by increased expression of HIF-1 $\alpha$  (the master regulator of metabolic adaptation to hypoxia), pro-inflammatory cytokines (IL-1 $\beta$ , IL-6), and pro-oxidative capacity. Strikingly, Chagas patients show augmented frequency of CD39+ monocytes and increased expression of CD73 per cell compared to healthy donors [74]. Thus, it is plausible that circulating monocytes promote ATP degradation to dampen the inflammatory microenvironment. Besides, leukocytes within cardiac explant from terminal Chagas disease patients exhibit a strong expression of CD73 and HIF-1 $\alpha$ , which positively correlates with the myocarditis degree and the local parasite burden (Fig. 2B) [75]. Regarding ATP receptors, the gene and protein expression of P2X7R are unaltered in circulating lymphocytes from patients with indeterminate form of Chagas disease [76].

In experimental models of Chagas disease, infected Swiss mice increase NTPDase and E-ADA activities in circulating lymphocytes and augment E-ADA activity in cardiac homogenates, although a reduction on tissue CD73 activity is found in the acute phase compared to uninfected controls [77]. Furthermore, E-NTPDase and E-ADA activities are higher in splenic lymphocytes of acutely *T. cruzi*-infected mice compared to uninfected controls. The prophylactic treatment with avian IgY (polyclonal immunoglobulins against *T. cruzi* parasite) prevents these alterations in ectoenzyme activities and reduces the parasitemia [78]. Similarly, our group has previously reported that transient pharmacological specific inhibition of CD73 in the murine acute phase of infection enhances the microbicidal M1-like macrophage subset, promotes a pro-inflammatory environment and diminishes cardiac parasite load. Likewise, *T. cruzi* infection of CD73KO mice leads to an enhanced cardiac antimicrobial immune response as it augments the frequency of M1-like macrophages with enhanced production of IL-12 and the microbicidal metabolite NO. Additionally, CD73-deficient mice presented increased CD8+ T cell effector functions which induces protection as observed by the reduced cardiac parasite burden compared to their WT counterpart (Fig. 2A) [79]. Thus, CD73 inhibition ameliorates the



**Fig. 2** Ectonucleotidases regulation of immune response against *Trypanosoma cruzi* infection. *T. cruzi* infection manipulates the expression of purinergic enzymes. **(A)** *T. cruzi*-infected CD73KO mice have an enhanced cardiac microbicidal immune response. CD73 abrogation diminishes IL-10 production of M2-like macrophages (*M2 Mac*) and augments the effector response (IL-12 and nitric oxide; NO) of M1-like macrophages (*M1 Mac*). CD73KO mice present augmented cytotoxic and pro-inflammatory (CD107a and IFN-

$\gamma$ ) CD8+T cell response, which induces protection as observed by the reduced parasite burden. **(B)** Patients with chronic asymptomatic Chagas disease show diminished ectonucleotidases expression (CD73 and CD39) in circulating lymphocytes and increased expression in monocytes. In human cardiac tissue, the augmented expression of CD73 positively correlates with the myocarditis severity and the cardiac parasite burden

outcome of chronic Chagas cardiomyopathy as it diminishes biochemical myocardial-specific injury marker (CK-MB) and improves the electrocardiographic characteristics [80].

It must be taken into account that parasites have catabolic ATP machinery which can affect the host's immune response favoring their virulence and persistence. In fact, different strains of *T. cruzi* parasites exhibit distinct levels of ATP-Dase hydrolytic activities. After treatment with ATPDase inhibitors, a marked reduction of trypomastigotes infectivity is observed in in vitro culture. Likewise, infection with Ecto-NTPDase-inhibited trypomastigotes leads to lower levels of parasitemia and higher mouse survival than infection with non-inhibited parasites [81]. Analogue products of purines (3'deoxyadenosine and deoxycoformycin) were used as antiparasitic treatments, and the observed therapeutic effect is due to an inability of trypanosomes to engage in new purine synthesis [82]. Hence, more studies are needed to elucidate whether it is possible to promote anti-*T. cruzi* immune response and at the same time inhibit parasite virulence factors.

Malaria is caused by five species of eukaryotic *Plasmodium* parasites transmitted by the bite of Anopheles spp. mosquitoes to humans. Malaria remains one of the most severe infectious diseases; it is responsible for hundreds of thousands of deaths predominantly among children in Africa. Purine signaling modulation seems to have relevant importance for *Plasmodium* parasites infectivity and malaria blood stage. Several studies have shown E-NTPDase to be involved in the infectivity of *P. falciparum* due to its

relevance for parasite life cycle [83]. Inhibition of purinergic signaling by apyrase inhibitors impairs *P. falciparum* replication and reduces red blood cells (RBC) infection [84]. Indeed, mammalian RBCs express ADORA2b and several P2Y and P2X receptors on their surface [85]. In experimental cerebral malaria the expression of several P2X and P2Y receptors is altered after *P. berghei* infection [86]. However, to date little is known about purinergic modulation of malaria-specific immune response. Recent studies suggest that the expression of P2X7R in CD4+T cells could be critical for Th1 profile development and IL-2 and IFN- $\gamma$  production during chronic *P. chabaudi* infection, while increasing the T follicular helper (Tfh) cell population [87]. P2X7R-deficient mice present increased susceptibility to infection, which is associated with impaired Th1 response. Furthermore, infected children with severe malaria show augmented expression of CTLA-4 and PD-1, while children with uncomplicated malaria show increased CD39+ and Granzyme B+CD4+T cells, indicating that distinctive regulatory mechanisms are triggered and may influence the clinical outcome of acute malaria [88].

Helminthiases are heterogeneous diseases caused by helminths, which are large multicellular pathogens that affect one-quarter of the human population. On the other hand, helminths are mainly controlled and eradicated by a canonical type 2 immune response [89]. The mammalian immune system needs to initiate rapid and effective anti-helminth mechanisms while simultaneously organizing the repair of inflicted mechanical damage to re-establish homeostasis

and prevent immunopathology. Although two antiparasitic drugs (moxidectin in 2018 and triclabendazole in 2019) have been recently approved by the FDA to treat helminthiasis, these infectious diseases continue to be an important health problem, mainly among the poorest population [90]. Regarding purinergic modulation of anti-helminth type 2 immune responses, ADO is reported to play a protective role. Patel and colleagues reported that ADO signaling through ADORA2a induces *Heligmosomoides polygyrus* worm expulsion and a robust associated development of type-2 immune response. Mice genetically deficient in ADORA2a receptor exhibit increased *H. polygyrus* parasite load, decreased M2 macrophages and eosinophils recruitment and reduced IL-4 and IL-13 production against the tissue-dwelling parasites [91]. On the other hand, CD39 ectoenzyme activity has a controversial role in filariasis, a chronic helminth infection. Patients infected with filarial nematodes, such as *Mansonella ozzardi*, exhibit augmented frequency of circulating CD39+CD4+T cells compared to control donors, which correlates with the filarial parasite load. Infected patients also present decreased plasma TNF, IL-8 and IL-6 levels than their non-infected counterparts. Besides, CD39 inhibition decreases lymphocyte proliferation in vitro and pro-inflammatory cytokine response [92]. Moreover, during murine *Schistosoma mansoni* infection, mesenteric endothelial cells increase the expression of NTP-Dases 2 and 3 favoring local ATP hydrolysis and mononuclear cell adhesion via P2Y1R. This mechanism may contribute to mesenteric inflammation and infection morbidity [93]. Some authors propose the purinergic signaling as a potential target to reduce schistosomiasis morbidity [94]. In fascioliasis, an infectious disease caused by *Fasciola hepatica*, the purinergic pathway modulation depends on the phase of infection. In the acute phase, a decrease in NTPDase activity in serum and an increase in the ectoenzyme activity in the liver are observed. In contrast, after the establishment of chronic infection, an increase in NTPDase and 5' nucleotidase activities is found in both periods of infection. The modulation of purinergic environment may generate high ADO levels, which promotes host protection due to tissue injury caused by chronic infection [95]. Altogether, these findings reveal the direct involvement of purinergic pathways in immune response modulation in several parasitic infections. Given the current unmet medical need for novel pharmacological approaches, further studies are needed to deepen the knowledge in the molecular mechanisms and provide supporting evidence to evaluate purinergic target candidates for the treatment of neglected parasitic disease.

## Bacterial infections

Tuberculosis (TB) is one of the most widely spread infectious disease and one of the major causes of mortality, since about two million people die annually because of this

disease. It is caused by *Mycobacterium tuberculosis* and, less frequently, *M. bovis*. The lung is the portal of *M. tuberculosis*, as transmission occurs upon inhalation of aerosolized bacilli coughed from the lungs of infected individuals, so TB is primarily a pulmonary disease. However, it has many other manifestations, affecting bones, the central nervous system, among many other systems. The immune response against TB infection has been reported to be modulated by the purinergic pathway. TB patients present an increased Treg cell population (CD4+CD25<sup>high</sup>CD39+) with regulatory properties. Depletion of CD39+Treg cells significantly augments anti-TB T cell responses in vitro [96]. Likewise, CD39 mediates suppressive functions in CD8+Treg cells in patients with active TB [97]. These reports suggest that CD39 plays an important role in the immunosuppression exerted by human Treg cell populations, possibly contributing to the balance between immune-mediated suppression and immunopathology in patients with TB. The CD73 ectoenzyme has also been described to modulate the anti-mycobacterial immune response. Indeed, CD73 activity restricts the early influx of neutrophils to the infected lungs without affecting bacterial load and spreading [98].


Purinergic receptors also have a role in determining the outcome of TB. P2X7R signaling in macrophages had a detrimental role in severe TB infection. Intracellular proliferation of high-virulent mycobacteria results in massive macrophage damage, ATP release and activation of P2X7R augment macrophage necrosis and spread the bacilli. Therefore, infected WT mice exhibit wide lung leukocyte infiltration and high mortality, in contrast to infected P2X7RKO mice, which showed moderate leukocyte infiltrates with ameliorated lung pathology [99]. Similarly, P2X7R signaling blockade with the antagonist BBG during experimental advanced pulmonary TB prevents the development of severe form of TB pathology in mice [100]. Additionally, chimeric WT mice with adoptive transfer of P2X7RKO hematopoietic cells show lower lung *M. bovis* bacterial burden and reduced pneumonia compared to WT mice. Lung necrosis and bacterial spreading to the spleen and liver are also diminished, suggesting that P2X7R in hematopoietic cells play a central role in the progression to severe TB [101]. In contrast to the results observed with high-virulence *M. tuberculosis* and *M. bovis* strains [99, 101], another report showed that P2X7RKO mice infected with less virulent *M. tuberculosis* exhibit augmented bacillary load in the lungs and increased Treg population but decreased B cells compared to WT mice [102]. Additionally, the potentiation of P2X7R augments inflammasome activation, resulting in the limitation of mycobacterial proliferation [103]. Indeed, patients with polymorphism in 1513C allele from P2X7R gene have increase susceptibility to extrapulmonary TB [104]. Given these results, it is plausible to speculate that immune response downstream P2X7R activation depends

on the mycobacterial virulence. ATP/P2X7R axis seems to be essential in the inflammasome-dependent IL-1 $\beta$  production and pathogen clearance in vivo in different bacterial infections (Fig. 3) [105, 106]. On the other hand, a critical modulatory function was assigned to the ADORA2a receptor during severe TB. AMP regulates macrophage state through ADORA2a receptor signaling. After ATP stimulation, it was quickly hydrolyzed to AMP, which downregulates inflammatory response and chemokine family genes, as well as strongly upregulates genes related to tissue repair, wound healing and angiogenesis [107]. In the same way, caffeine treatment, an ADORA2a receptor antagonist, enhances accumulation of CD4+ T cells with increased IFN- $\gamma$  production in the lungs and promotes mouse survival during severe TB [108].

*Streptococcus pneumoniae* infection causes different illnesses, such as pneumonia, bacteremia and meningitis. *S. pneumoniae* interferes with the purinergic signaling by the induction of P2Y2R internalization in pulmonary epithelial cells in vitro, suggesting that bacteria may exert purinergic-dependent evasion mechanisms to promote infection [109]. Nevertheless, the host creates an adenosinergic microenvironment to be protected from exacerbated inflammation during infection. ADA-inhibited mice exhibit increased resistance to infection and ten-thousand-fold diminished bacterial load in the lungs and undetectable bacteremia. In contrast, CD73 pharmacologic inhibition induces increased susceptibility with higher pulmonary bacterial burden and increased bacteremia compared to mock-treated mice. The mechanism underlying this effect seems to be executed by ADO since it downregulates the neutrophil infiltration and

their bactericidal ability, and the absence of these regulatory mechanisms is reported to be detrimental to the host [110]. Confirming this speculation, the authors found that CD73 augments neutrophil bactericidal activity by inhibiting IL-10 production, which is essential for ROS secretion [111]. On the other hand, ADORA1R signaling was reported to inhibit bacterial binding to human lung epithelial cells increasing host resistance to pulmonary infection [112]. Likewise, CD73-dependent ADO production signaling via ADORA2a receptor on B cells promotes isotype switch and regulates antibody response against *S. pneumoniae* infection. Stimulation of ADORA2a receptor with CGS21680 agonist augments IgG3 antibody protection in vaccinated young mice and enhanced survival after challenge [113]. On the other hand, ADORA2bR deficiency promotes extracellular bactericidal activity in neutrophils, enhancing NETs production. Indeed, ADORA2bR-deficient mice show diminished lung bacterial load and improved survival [114].

It has been also well-documented that purinergic signaling modulates immunity against enteropathogenic infections [115]. CD73 is highly expressed in the colonic epithelium, more specifically in the apical surface of intestinal epithelial cells (IECs). CD73 knockdown (KD) in IECs protects against *Salmonella* colitis as demonstrated by less marked weight loss and decreased colon shortening. CD73KD mice also show reduced bacterial translocation to the lumen and decreased *Salmonella* load in mesenteric lymph nodes, spleen and liver, suggesting that ADO promotes initial invasion and systemic dissemination [116]. *Salmonella* infection also induces downregulation of CD39 and CD73 ectoenzymes in CD4+ T cell population. Inhibition



**Fig. 3** P2X7R dual function in *Mycobacterium tuberculosis* infection. P2X7R activation plays a crucial role in control of infectious diseases. ATP-induced P2X7R activation may participate in the control of *M. tuberculosis* by improving intracellular pathogen killing and triggering the assembly and activation of the inflammasome and the consequent release of pro-inflammatory cytokines, such as IL-1 $\beta$ .

However, its role in the host defense against *M. tuberculosis* infection is still controversial, due to its strong pro-inflammatory and cytotoxic activity; it may potentiate tuberculosis progression and the associated tissue damage. High concentrations of ATP can activate the P2X7R and induce the necrosis of infected cells leading to the spread of the bacilli and worsening the disease



of CD73 enzymatic activity in *Salmonella* whole cell lysate (WCL)-treated cells increases pro-inflammatory cytokine production, such as IFN- $\gamma$ , TNF and IL-1 $\beta$  and inducible nitric oxide synthase (iNOS), leading to a more efficiently elimination of *Salmonella* bacteria compared to infected WT cells [117]. In addition, CD73 inhibition of *Salmonella* WCL-treated macrophages enhances the production of NO, pro-inflammatory cytokines IL-1 $\beta$  and TNF. Phagocytosis and intracellular killing are significantly higher in the APCP (CD73 inhibitor)-treated macrophages and in CD73KO peritoneal macrophages than untreated and CD73-competent macrophages [118]. Altogether, these results suggest that inhibiting ADO formation promotes pro-inflammatory and bactericidal functions in macrophage and improves the host's resistance to *Salmonella* infection. On the other hand, it has been also reported that P2X7R restricts Tfh cell expansion and germinal center reaction in the Peyer's patches in the setting of this infection. Depleting extracellular ATP, via administration of exogenous apyrase, increases the induction of specific IgA in response to *Salmonella* infection or an inactivated oral vaccine providing better protection from secondary infection [119]. Thus, preventing ATP accumulation could also be favorable for the improvement of the immune response against *Salmonella* infection.

Sepsis is a severe health condition caused by the exacerbated immune response to a microbial systemic infection. Extracellular ATP levels are augmented in the mouse model of polymicrobial sepsis induced by the cecal ligation and puncture (CLP). In this sense, several works have described the protective function of macrophages in septic conditions. ATP signaling in macrophages via P2X4R mediates a stimulatory effect on *E. coli* bacterial killing through augmented ROS production. P2X4R stimulation improves mouse survival by decreasing bacterial burden, pro-inflammatory cytokines, chemokine levels and spleen, liver and kidney injury in CLP-induced sepsis. As a logical consequence, pharmacological stimulation with ivermectin, a P2X4R agonist, protects the host against bacterial dissemination and mortality in sepsis [120]. Indeed, ADORA2b-deficient macrophages exhibit increased bacteria phagocytosis capacity, while ADORA2bKO mice show decreased peritoneal bacterial load and improved survival in a CLP model of sepsis [121]. Likewise, accumulation of adenosine by expanded CD39+ plasmablast subpopulation impairs macrophage bacterial killing and promotes IL-10 production via ADORA2a signaling in septic mice [122]. Besides, employing this mouse model of sepsis, Haskó and colleagues describe a protective role of P2X7R in macrophages by diminishing bacterial load and production of pro-inflammatory cytokines and chemokines, as well as improving mouse survival [123].

Purinergic signaling is also essential for TLR4-induced mitochondrial ATP synthesis and autocrine signaling, required for monocyte/macrophage activation,

inflammasome assembly and IL-1 $\beta$  production [124]. ADP protects mice from *E. coli*-induced peritonitis by enhancing MCP-1-dependent recruitment of macrophages to the infected tissues. Both P2Y12R and P2Y13R deficiency inhibit the ADP-mediated immune response and promotes *E. coli* persistence in infected mice [125]. In the same way, P2X4R- and P2X7R-deficient mice have enhanced susceptibility to sepsis induced by uropathogenic *E. coli* and are more prone to die from a severe infection compared to WT mice. Higher systemic bacterial burden, plasmatic pro-inflammatory cytokines levels and activated coagulation cascade with increased levels of thrombin–antithrombin complexes are associated with their increased mortality [126]. Similarly, constant intravenous infusion with P2X1R antagonist markedly accelerates development of a septic response to *E. coli*-induced bacteremia. P2X1R antagonist-treated mice died at early times post-infection with high bacteremia and hematuria, substantially elevated plasmatic pro-inflammatory cytokines levels, massive intravascular coagulation and a concomitant reduction in circulating platelets [127]. Conversely, ATP-induced P2XR activation in vitro has a key role in the cytotoxic effects of  $\alpha$ -hemolysin and leukotoxin A on THP-1 human monocytes. Inhibition of P2X1R, P2X4R or P2X7R significantly reduce THP-1 cytolysis protecting macrophage/monocyte phagocytosis function [128]. In vitro experiments also revealed that ATP signaling via P2X7R inhibits J774 macrophage phagocytosis of bio-particles coated with *S. aureus* or *E. coli*. A438079, an antagonist of P2X7R, partially reverts the effect of ATP on bacterial phagocytosis [129].

During *Staphylococcus aureus* infection, the signaling via P2X7R has been described as favorable for the elimination of the bacterial infection. Human macrophages internalize antimicrobial peptide LL-37 derived from neutrophils via a P2X7R-dependent mechanism, primarily involving a clathrin-dependent endocytosis pathway. P2X7R signaling in macrophages enhances intracellular ROS production and accumulation of lysosomes, which promote intracellular *S. aureus* elimination [130]. Similarly, P2XR inhibitors interfere with binding and oligomerization of hemolysin A from *S. aureus* (Hla) with cell membranes. The P2XR antagonists restrict the function of a membrane pore-forming toxin through non-canonical mechanisms. The data suggest the need for a critical revision of the notion that P2XRs are enhancers of membrane pore-forming toxin-dependent hemolysis. The role of ATP release and P2XR signaling in destabilizing the membrane stability and induction of pore formation is still controversial [131]. In line with this, several selective P2X7R antagonists inhibited *Clostridium perfringens* beta-toxin-induced cytotoxicity in THP-1 cells [132]. Finally, it has been shown that several bacteria exploit the production of ADO to dampen inflammation and support their survival during infection [133]. Summing up, the

findings described clearly illustrate that different pathogenic bacteria may exert their evasion mechanisms based on the production of purinergic metabolites, promoting an immunosuppressive microenvironment to persist in the host and establish a chronic disease. On the other hand, microbiota also can manage the purinergic system to its favor. Further investigations are needed to completely visualize the role of purinergic signaling in the host–bacteria interplay.


## Viral infections

One of the most serious public health problems globally is HIV type 1 (HIV-1) infection since 38 million people are infected worldwide, and almost two million new infections occur each year. Antiretroviral therapies (ART) have allowed infected people to benefit from a better general state of health by significantly increasing their life expectancy thanks to the sustained suppression of viremia. Nevertheless, infected patients suffer from co-morbidities due to chronic inflammation derived from coinfections and immune dysregulation. Several studies emphasize the role of the purinergic pathway in the sustained inflammation and in different cellular processes of the acquired immunodeficiency syndrome (AIDS), usually associates with HIV-1 infection [134, 135]. HIV-1 infects several immune cells such as CD4+ T cells, myeloid dendritic cells and monocyte macrophages, all populations sharing the expression of CD4 receptor along with the chemokines receptors CCR5 and/or CXCR4. Indeed, untreated infected patients present increasing immunodeficiency with decreasing CD4+ T cell counts and a reversed CD4+/CD8+ T cells ratio.

Although it is not fully addressed, ADO contributes to the suppression of CD4+ T cell responses during HIV infection. Numerous authors had reported that the expression of CD39 is upregulated in Treg cells compared to activated CD4+ T cells in HIV+ patients. Regulatory functions of Treg cells are diminished by blocking with anti-CD39 antibody in a co-culture of Treg and CD8+ T cells. Furthermore, it was also shown that the expansion of CD39+ Treg cells inversely correlates with CD4+ T cells counts in treated patients [136]. In line with this, IL-2 production by activated CD4+ T cells is suppressed by CD39+ Treg cells via ADO/cAMP enzymatic pathway. Increased expression of ADORA2a receptor and intracellular cAMP levels in CD4+ T cells of HIV-infected patients diminishes IL-2 production and inhibits T cell proliferation [137]. Treg cells serve as viral reservoirs during chronic infection. Patients with advanced AIDS exhibit increased CD39 expression, and the CD39+ naïve Treg frequency directly correlates with HIV DNA levels [138]. Altogether, these findings suggest that CD39 pathway in Treg cells may be playing a deleterious role in the progression of HIV infection by suppressing CD4+ and

CD8+ T cell responses and contributing to chronic inflammation and T cell dysfunction. Another mechanism that may be responsible for the AIDS pathogenesis is the significantly augmented frequency of CD39+ CD56<sup>bright</sup> NK cells, observed in untreated HIV patients. This NK cell subpopulation is associated with an increased viral load, lower CD4+ T cell count and disease progression. Indeed, the authors propose CD39 as a marker of a regulatory NK subpopulation, since it exhibits increased AhR expression and IL-10 production [139]. Moreover, CD73 is also involved in the regulation of T cell activation. Contrasting to CD39+ Treg subset, CD73+ cells do not express FoxP3 and CD25 at high levels; thus, CD73+ CD4+ T cells represent a phenotypically and functionally different subpopulation [140]. CD73+ CD4+ T cell subset is preferentially depleted in HIV+ patients compared to healthy controls, regardless of viral load and treatment. This subset depletion suggests the existence of an ADO-diminished microenvironment that may be unable to prevent persistent immune activation. Supporting this idea, an inverse correlation was shown between the CD73+ CD4+ T cell count and T cell activation, as well as plasma C reactive protein levels [141]. Additionally, HIV-infected patients show diminished expression of CD73 on CD8+ T cells, which is correlated with disease progression and partially reverts after effective ART [142]. Besides, CD73 is involved in the expansion of HIV-specific CD8+ T cells, whereas CD73 expression is higher in memory CD8+ T cell subset. The frequency of CD73+ CD8+ T cells is inversely associated with cell activation and plasma viral load. Interestingly, HIV controllers express high levels of CD73 [143]. Besides, untreated chronic patients present lower frequency of CD39+ CD73+ B cells compared to ART-treated patients and healthy controls. Downregulation of CD73 on B cells is associated with augmented expression Ki67+ and PD-1. In addition, CD73 loss also correlates with low CD4+ T cell counts, higher expression of markers of cellular proliferation and exhaustion, such as Ki-67 and PD-1, and decreased in vitro AMP catabolic activity and IgG switch ability dysregulation [144]. All these results in HIV+ patients are depicted in Fig. 4.

Another component of the purinergic system that is associated with increased immune activation is ADA due to its potential to reverse immunosuppression driven by extracellular ADO. It has been shown that in both healthy and HIV-infected individuals, ADA is associated with increased expression of costimulatory molecules CD80, CD83, CD86 and CD40, promoting the maturation of DCs regardless of its enzymatic activity as shown after desalting and treatment with HgCl<sub>2</sub>. ADA treatment enhances DCs immunogenicity and promotes their capacity to stimulate allogenic T cell subpopulations to proliferate [145]. In line with this, it has also been shown that in autologous co-cultures of T cells with HIV-1 peptide-pulsed DCs, the addition of ADA leads to a



**Fig. 4** Purinergic dysregulation in untreated HIV + patients with high viral loads. **(A)** CD39+Tregs suppress *in vitro* IL-2 production by activated CD4+ T cells via adenosine/cAMP enzymatic pathway. **(B)** CD4+ and CD8+ T cells subsets expressing CD73 ectoenzyme are preferentially depleted in HIV+ patients compared to healthy controls, regardless of viral load and treatment. **(C)** Untreated chronic patients present diminished frequency of CD39+CD73+ B cells.

In fact, the downregulation of CD73 expression on B cells is associated with augmented cellular proliferation (Ki67+) and exhaustion phenotype (PD-1+). **(D)** CD39+CD56<sup>bright</sup> NK cell subset presents increased AhR expression and IL-10 production and is associated with lower CD4+ T cell counts, higher viral loads and disease progression.

reduction in Treg frequency and to a significant enhancement of HIV-1-specific effector CD4+ T cells in a dose-dependent manner. At the same time, ADA addition increases the secretion of Th1 inflammatory cytokines and proliferation of CD8+ T cells, demonstrating that ADA treatment could improve the immune subpopulations involved in the control of HIV-1 infection [146]. These results are in agreement with previous reports showing that the addition of extracellular ATP to the co-cultures also inhibits the propagation of HIV-1 from the immature DCs to autologous CD4+ T lymphocytes [147]. ADA-1 modulates the program of circulating and germinal center Tfh cells, enhancing their function. This mechanism promotes effective collaboration between T and B cells and the generation of antibodies, by influencing the production of IL6/IL-2 and controlling the expression of CD26 and the ADORA signaling. The authors suggest that ADA represents a potential target for the development of Tfh-targeted vaccine strategy [148].

It should be noted that purinergic signaling has been associated with both a protective and pathological role in different viral infections. The role of adenosine pathway signaling in HIV infection has been addressed in [149]. For example, HIV infection of CD4+ T cell induces Panx1 hemichannels opening, required for effective HIV replication in CD4+ T lymphocytes [150]. Furthermore, ATP activates P2Y2R and induces activation tyrosine kinase 2 and transient depolarization of the plasma membrane, which stimulates fusion between the envelope protein and CD4-containing membranes [151]. On the other hand, P2X1R inhibition has been reported to block HIV-1 entry and replication within target cells [152]. Inhibition of P2X1R, P2X7R and P2Y1

significantly reduces viral replication within human macrophages, whereas P2X1R antagonists block viral entry to the cell. The data also indicate that binding gp120 protein results in the rapid ATP release from macrophages and allows autocrine P2R activation, facilitating HIV infection [153]. In the same way, the ecto-ATPase activity increases in *in vitro* HIV-1-infected human macrophages and its blockade prevents HIV-1 replication [154]. In fact, it has been proven that P2X1R and P2X7R selective antagonists abrogate both HIV-1 infection and the subsequent inflammation. The purinergic P2X1R and P2X7R antagonists inhibit HIV-1 infection, but only P2X1R antagonists downregulate IL-1 $\beta$  and IL-10 production in *ex vivo* infection of human tonsil [155]. It has been reported that P2X1R antagonist (NF279) inhibits the fusion with the HIV-1 cell membrane by blocking the virus binding and entrance via CXCR4 and CCR5 [156]. Moreover, blockade of P2XR signaling inhibits HIV-1 membrane fusion [157].

Extracellular ATP is capable of reducing the replication of DNA and RNA viruses through activation of P2X7R, enhancing the production and release of IFN- $\beta$ , which is crucial in promoting antiviral immunity [158]. This is also an essential antiviral mechanism against respiratory viruses. Adenovirus and Influenza viruses increase ATP and ADO levels in the respiratory tract. The induction of purinergic P2X7R signaling plays a key role in generating a robust inflammatory response capable of controlling these infections. If the infection persists, a systemic inflammatory response can be triggered, which is associated with higher mortality. Disruption of the ATP/P2X7R interaction avoids symptoms of acute respiratory distress syndrome (ARDS)

associated with less infiltration of neutrophils and macrophages and lower levels of pro-inflammatory cytokines, associated with an enhanced survival of mice after infection with Adenovirus [159] or Influenza virus [160]. In turn, a marked increase in morbidity and mortality is observed in P2Y2R-deficient mice in response to lung infection with the human respiratory syncytial virus. The lower survival of the P2Y2KO mice could be associated with the defective infiltration and response of Th1 cells and higher viral titers, evidencing the protective role of P2Y2 receptor in lung infections [161]. On the other hand, ADORA1R activation significantly contributes to the generation ARDS. Nevertheless, the activity of CD73 is not required to generate ARDS [162]; rather, ADO generation is due to the enzymatic action of tissue non-specific alkaline phosphatase, an enzyme present in the lung parenchyma with low affinity but high capacity to metabolize ATP/AMP in a non-specific way [163].

In December 2019, the new ARDS-related to Coronavirus 2 (SARS-CoV-2) infection that causes COVID-19 disease was reported for the first time in China. As already reported, severe cases are associated with hyper-activation of the immune system and an excessive release of cytokines called cytokines release syndrome (CRS). So far, Ahmadi and colleagues showed that circulating cytotoxic cells (CD8 + T cells, NK cells and NKT cells) express lower levels of CD73 ectoenzyme in COVID-19 patients compared to healthy donors. Furthermore, CD73+ and CD73- subpopulations of CD8 + T cells and NKT cells with different functionality are observed in COVID-19 patients. CD8 + T cells and NKT cells lacking CD73 exhibit increased cytotoxic effector capacity compared to their counterpart CD73 + [164]. P2X7R hyperactivation has been reported in COVID-19 as a key driver of inflammation and NLRP3 inflammasome activation [165, 166], potentially driving central nervous system diseases [165, 167]

Purinergic pathway also has been studied in endemic mosquito-borne viral diseases, such as dengue virus (DENV) infection. This represents the most common arboviral infection in humans and can generate a wide spectrum of clinical manifestations. In severe cases, higher mortality is associated with hyper-activation of the immune system. Through the addition of specific P2X7R inhibitors, several authors demonstrated that P2X7R signaling generates an increase in antiviral responses, either by augmenting NO and cytokine production in human monocytes [168] or by improving human T cell function, which provide an early source of IFN- $\gamma$  and killing DENV-infected cells [169]. Dengue hemorrhagic fever is a systemic endothelial dysfunction resulting from the prolonged and exacerbated immune response. Many proteins and signaling pathways are involved in maintaining the integrity of the endothelial barrier, including the CD73/ADO axis. Probably, the

endothelial infection with DENV decreases expression of CD73 and this could be associated with a recovery of endothelial barrier function [170].

Viral infections are the major causes of acute and chronic liver diseases such as hepatitis. Hepatotropic virus, such as hepatitis B virus (HBV) and hepatitis delta virus (HDV), requires the activity of P2XR to infect primary human hepatocytes [171]. In chronic hepatitis C virus (HCV)-infected patients, the expression of P2X1R, P2X4R and P2X7R in peripheral blood mononuclear cells increases compared to control patients. However, it remains to be elucidated whether the expression of purinergic receptors is associated with an antiviral immunity or participates in the pathophysiology of the disease [172, 173]. Furthermore, in patients that develop hepatocellular carcinoma (HCC) induced by a HCV infection, the P2X4R expression is increased compared to patients with HCC from non-viral causes [174]. Regarding the ectoenzymes, recently a population of CD39 + Treg cells was identified to be associated with potent immunosuppressive activity and the progression of viral infections. Tang and colleagues showed that the proportion of circulating CD39 + FoxP3 + Treg cells correlates positively with HBV viremia levels and, conversely, negatively correlates with markers of liver damage [175].

A prominent role of the purinergic system in intestinal function was demonstrated under physiological and pathological conditions. ADO plays a central role in intestinal functions, by modulating the interaction between enteric nervous system (ENS), smooth muscle and epithelial barrier function. Viral-induced ENS neurodysfunction is associated with a markedly altered ADO metabolism, with a spatial and functional reorganization of all ADORA receptors and an increased expression of ADA and CD73 ectoenzyme in the gut [176]. On the other hand, the treatment of different human cell lines with imiquimod, an antagonist of the ADORA1 receptor, suppresses the replication of HSV-1 [177]. Within the family of herpes viruses, the human cytomegalovirus (CMV) is a  $\beta$ -herpes virus that infects a large proportion of the population worldwide. Unlike what happens in immunocompetent people, it can cause severe diseases in immunosuppressed patients. In vitro studies show that several components of the purinergic signaling system play critical roles within CMV-infected cells. CMV infection induces P2Y2R and P2X5R expression in human fibroblasts. Whereas P2Y2R enhances CMV performance due to its importance for efficient virus gene expression, DNA synthesis and production of infectious progeny, the P2X5R reduces CMV production [178]. On the other hand, the purinergic system may be involved in the carcinogenesis of different chronic viral infections, such as Epstein-Barr virus (EBV)-associated and human papillomavirus (HPV)-related carcinomas [179, 180].

## Conclusions and therapeutic perspectives

For several decades, the purinergic system has been extensively studied as possible therapeutic target for inflammatory, autoimmune and oncological diseases [181–186]. Inflammation drives the expression of purinergic components and subsequent, activation of purinergic signaling to prevent tissue collateral damage. After infection, extracellular ATP supports the establishment of a set point of various signaling pathways and affects the responses of immune cells. Therapies targeting increased ATP and P2 receptor signaling may be fundamental in controlling the collateral injury and maintaining healthy tissues for the survival of the host in the acute phase of infection. In particular, ATP-P2X7R pathway inhibition may be potentially effective for therapeutic development [44]. ATP catabolism to ADO remarkably increases as a result of the activities of extracellular ecto-apyrases, ecto-ATPases and ectonucleotidases. Rapid uptake and metabolism of ADO maintains its low levels in healthy and unstressed cells or tissues, but during inflammatory conditions this equilibrium breaks down and extracellular ADO level rises substantially. The imbalance of the purinergic microenvironment and its signaling mechanism can trigger immune exacerbation or suppression. Resulting purinergic microenvironment and receptor signaling certainly have a fundamental role as mediators of host immune response and pathogen interaction. Indeed, adenosinergic pathway inhibitors may reinvigorate the immune cell effector functions and improve immune response fitness [187]. Better understanding of the effect of ADO on both host innate and adaptive immune system function in chronic infectious diseases is required to avoid the persistence of the microbe and the progression of the disease [188].

Ectonucleotidases from the microorganisms are major tools to escape from innate and adaptive immunity and should be taken into account as potential targets for new therapeutic approaches, and also, vaccines development [189, 190]. In some cases, the host's own organism generates an anti-inflammatory microenvironment to prevent vital organs damage and promote survival, thus allowing the microorganism to replicate without having to hide or fight a robust immune response against it. The persistence of numerous microorganisms is improved by their ability to modulate the release of nucleotides and nucleosides and signal host parenchymal and immune cells. Depletion of extracellular nucleotides or pharmacological inhibition of purinergic receptors during certain infections may represent effective strategies to prevent infectious disease. Further investigations will precisely define the molecular actors of these processes and hence might identify a series of novel druggable targets for the treatment of microbial infections.

**Acknowledgements** MPA is member of the scientific career from the Consejo Nacional de Investigaciones Científicas y Técnicas de la República Argentina (CONICET). NE and GB thank CONICET for the fellowships. YLMM thanks fellowship granted from ANPCyT-FON-CyT. Figures were created with BioRender (<https://biorender.com>).

**Authors' Contributions** NE developed the concept and performed the bibliographic search. NE, GB, YLMM and MPA wrote the manuscript. NE, GB, YLMM and MPA were responsible for figures design. NE, GB, and YLMM and MPA carefully revised the manuscript.

**Funding** This work was supported by Secretaría de Ciencia y Tecnología, Universidad Nacional de Córdoba (113/17), Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) Fondo para la Investigación Científica y Tecnológica (PICT2015–1130 and PICT2017–1218), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP11220120100620) and Ministerio de Ciencia y Tecnología, Gobierno de la Provincia de Córdoba (114/18).

**Availability of data and material/Code availability** Not applicable.

## Declarations

**Conflicts of interest** The authors declare that there is no conflict of interest.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

## References

- Villani AC, Sarkizova S, Hacoen N (2018) Systems Immunology: Learning the Rules of the Immune System. *Annu Rev Immunol* 36:813–842. <https://doi.org/10.1146/annurev-immunol-042617-053035>
- Cekic C, Linden J (2016) Purinergic regulation of the immune system. *Nat Rev Immunol* 16(3):177–192. <https://doi.org/10.1038/nri.2016.4>
- Di Virgilio F, Vuerich M (2015) Purinergic signaling in the immune system. *Auton Neurosci* 191:117–123. <https://doi.org/10.1016/j.autneu.2015.04.011>
- Burnstock G, Boeynaems JM (2014) Purinergic signalling and immune cells. *Purinergic Signal* 10(4):529–564. <https://doi.org/10.1007/s11302-014-9427-2>
- Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. *Biochem Biophys Acta* 1783(5):673–694. <https://doi.org/10.1016/j.bbamcr.2008.01.024>
- Bodin P, Burnstock G (2001) Purinergic signalling: ATP release. *Neurochem Res* 26(8–9):959–969. <https://doi.org/10.1023/a:1012388618693>
- Burnstock G (2018) Purine and purinergic receptors. *Brain Neurosci Adv* 2:2398212818817494. <https://doi.org/10.1177/2398212818817494>
- Corriden R, Insel PA (2010) Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. *Sci Signal* 3(104):re1. <https://doi.org/10.1126/scisignal.3104re1>

9. Junger WG (2011) Immune cell regulation by autocrine purinergic signalling. *Nat Rev Immunol* 11(3):201–212. <https://doi.org/10.1038/nri2938>
10. Faas MM, Saez T, de Vos P (2017) Extracellular ATP and adenosine: The Yin and Yang in immune responses? *Mol Aspects Med* 55:9–19. <https://doi.org/10.1016/j.mam.2017.01.002>
11. Antonioli L, Pacher P, Vizi ES, Hasko G (2013) CD39 and CD73 in immunity and inflammation. *Trends Mol Med* 19(6):355–367. <https://doi.org/10.1016/j.molmed.2013.03.005>
12. Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. *Trends Immunol* 25(1):33–39. <https://doi.org/10.1016/j.it.2003.11.003>
13. Soderback U, Sollevi A, Fredholm BB (1987) The disappearance of adenosine from blood and platelet suspension in relation to the platelet cyclic AMP content. *Acta Physiol Scand* 129(2):189–194. <https://doi.org/10.1111/j.1748-1716.1987.tb08058.x>
14. Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. *Nature* 509(7500):310–317. <https://doi.org/10.1038/nature13085>
15. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science* 314(5806):1792–1795. <https://doi.org/10.1126/science.1132559>
16. Junger WG (2008) Purinergic regulation of neutrophil chemotaxis. *Cell Mol Life Sci* 65(16):2528–2540. <https://doi.org/10.1007/s00018-008-8095-1>
17. Wang X, Chen D (2018) Purinergic Regulation of Neutrophil Function. *Front Immunol* 9:399. <https://doi.org/10.3389/fimmu.2018.00399>
18. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature* 461(7261):282–286. <https://doi.org/10.1038/nature08296>
19. Regateiro FS, Cobbold SP, Waldmann H (2013) CD73 and adenosine generation in the creation of regulatory microenvironments. *Clin Exp Immunol* 171(1):1–7. <https://doi.org/10.1111/j.1365-2249.2012.04623.x>
20. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC (2007) CD39 and control of cellular immune responses. *Purinergic Signal* 3(1–2):171–180. <https://doi.org/10.1007/s11302-006-9050-y>
21. Desai BN, Leitinger N (2014) Purinergic and calcium signaling in macrophage function and plasticity. *Front Immunol* 5:580. <https://doi.org/10.3389/fimmu.2014.00580>
22. Hasko G, Pacher P, Deitch EA, Vizi ES (2007) Shaping of monocyte and macrophage function by adenosine receptors. *Pharmacol Ther* 113(2):264–275. <https://doi.org/10.1016/j.pharmthera.2006.08.003>
23. Hamidzadeh K, Mosser DM (2016) Purinergic Signaling to Terminate TLR Responses in Macrophages. *Front Immunol* 7:74. <https://doi.org/10.3389/fimmu.2016.00074>
24. Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM (2013) TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. *Blood* 122(11):1935–1945. <https://doi.org/10.1182/blood-2013-04-496216>
25. Csoka B, Selmezy Z, Koscsó B, Nemeth ZH, Pacher P, Murray PJ, Kepka-Lenhart D, Morris SM Jr, Gause WC, Leibovich SJ, Hasko G (2012) Adenosine promotes alternative macrophage activation via A2A and A2B receptors. *FASEB J* 26(1):376–386. <https://doi.org/10.1096/fj.11-190934>
26. Barbera-Cremades M, Baroja-Mazo A, Pelegrin P (2016) Purinergic signaling during macrophage differentiation results in M2 alternative activated macrophages. *J Leukoc Biol* 99(2):289–299. <https://doi.org/10.1189/jlb.1A0514-267RR>
27. Hasko G, Pacher P (2012) Regulation of macrophage function by adenosine. *Arterioscler Thromb Vasc Biol* 32(4):865–869. <https://doi.org/10.1161/ATVBAHA.111.226852>
28. Cohen HB, Ward A, Hamidzadeh K, Ravid K, Mosser DM (2015) IFN-gamma Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response. *J Immunol* 195(8):3828–3837. <https://doi.org/10.4049/jimmunol.1501139>
29. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, Verderio C, Buer J, Scanziani E, Grassi F (2008) Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. *Sci Signal* 1(39):ra6. <https://doi.org/10.1126/scisignal.1160583>
30. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, Ricordi C, Westendorf AM, Grassi F (2011) ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. *Sci Signal* 4(162):ra12. <https://doi.org/10.1126/scisignal.2001270>
31. Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC (2018) The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. *Nature* 559(7713):264–268. <https://doi.org/10.1038/s41586-018-0282-0>
32. Borges da Silva H, Peng C, Wang H, Wanhainen KM, Ma C, Lopez S, Khoruts A, Zhang N, Jameson SC (2020) Sensing of ATP via the Purinergic Receptor P2RX7 Promotes CD8(+) Trm Cell Generation by Enhancing Their Sensitivity to the Cytokine TGF-beta. *Immunity* 53(1):158–171 e156. <https://doi.org/10.1016/j.immuni.2020.06.010>
33. Lappas CM, Rieger JM, Linden J (2005) A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. *J Immunol* 174(2):1073–1080. <https://doi.org/10.4049/jimmunol.174.2.1073>
34. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. *Blood* 111(1):251–259. <https://doi.org/10.1182/blood-2007-03-081646>
35. Ohta A, Sitkovsky M (2014) Extracellular adenosine-mediated modulation of regulatory T cells. *Front Immunol* 5:304. <https://doi.org/10.3389/fimmu.2014.00304>
36. Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Uman'sky V (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *Br J Cancer* 120(1):16–25. <https://doi.org/10.1038/s41416-018-0333-1>
37. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rotzschke O, Falk K (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. *Blood* 110(4):1225–1232. <https://doi.org/10.1182/blood-2006-12-064527>
38. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 204(6):1257–1265. <https://doi.org/10.1084/jem.20062512>
39. Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM, Pan F, Priel A, Clish CB, Robson SC, Quintana FJ (2015) Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. *Nat Med* 21(6):638–646. <https://doi.org/10.1038/nm.3868>

40. Takenaka MC, Robson S, Quintana FJ (2016) Regulation of the T Cell Response by CD39. *Trends Immunol* 37(7):427–439. <https://doi.org/10.1016/j.it.2016.04.009>
41. Dong K, Gao ZW, Zhang HZ (2016) The role of adenosinergic pathway in human autoimmune diseases. *Immunol Res* 64(5–6):1133–1141. <https://doi.org/10.1007/s12026-016-8870-2>
42. Antonioli L, Blandizzi C, Pacher P, Hasko G (2013) Immunity, inflammation and cancer: a leading role for adenosine. *Nat Rev Cancer* 13(12):842–857. <https://doi.org/10.1038/nrc3613>
43. Coutinho-Silva R, Ojcius DM (2012) Role of extracellular nucleotides in the immune response against intracellular bacteria and protozoan parasites. *Microbes Infect* 14(14):1271–1277. <https://doi.org/10.1016/j.micinf.2012.05.009>
44. Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 Receptor in Infection and Inflammation. *Immunity* 47(1):15–31. <https://doi.org/10.1016/j.immuni.2017.06.020>
45. Paletta-Silva R, Meyer-Fernandes JR (2012) Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases. *J Trop Med* 2012:650874. <https://doi.org/10.1155/2012/650874>
46. Paes-Vieira L, Gomes-Vieira AL, Meyer-Fernandes JR (2018) NTPDase activities: possible roles on *Leishmania* spp infectivity and virulence. *Cell Biol Int* 42(6):670–682. <https://doi.org/10.1002/cbin.10944>
47. Rai AK, Thakur CP, Velpandian T, Sharma SK, Ghosh B, Mitra DK (2011) High concentration of adenosine in human visceral leishmaniasis despite increased ADA and decreased CD73. *Parasite Immunol* 33(11):632–636. <https://doi.org/10.1111/j.1365-3024.2011.01315.x>
48. Vijayamahantesh AA, Dikhit MR, Mishra A, Singh AK, Das VN, Das P, Bimal S (2017) Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. *Cytokine* 91:170–179. <https://doi.org/10.1016/j.cyto.2017.01.001>
49. Vijayamahantesh AA, Kumar S, Dikhit MR, Jha PK, Singh AK, Sinha KK, Pandey K, Das VN, Das P, Bimal S (2016) Up regulation of A2B adenosine receptor on monocytes are crucially required for immune pathogenicity in Indian patients exposed to *Leishmania donovani*. *Cytokine* 79:38–44. <https://doi.org/10.1016/j.cyto.2015.12.016>
50. Rai AK, Kumar P, Saini S, Thakur CP, Seth T, Mitra DK (2016) Increased level of soluble adenosine deaminase in bone marrow of visceral leishmaniasis patients: an inverse relation with parasite load. *Acta Parasitol* 61(3):645–649. <https://doi.org/10.1515/ap-2016-0087>
51. Basu M, Gupta P, Dutta A, Jana K, Ukil A (2020) Increased host ATP efflux and its conversion to extracellular adenosine is crucial for establishing *Leishmania* infection. *J Cell Sci* 133(7). <https://doi.org/10.1242/jcs.239939>
52. Lima MHF, Sacramento LA, Quirino GFS, Ferreira MD, Benevides L, Santana AKM, Cunha FQ, Almeida RP, Silva JS, Carregaro V (2017) *Leishmania infantum* Parasites Subvert the Host Inflammatory Response through the Adenosine A2A Receptor to Promote the Establishment of Infection. *Front Immunol* 8:815. <https://doi.org/10.3389/fimmu.2017.00815>
53. Chaves SP, Torres-Santos EC, Marques C, Figliuolo VR, Persechini PM, Coutinho-Silva R, Rossi-Bergmann B (2009) Modulation of P2X(7) purinergic receptor in macrophages by *Leishmania amazonensis* and its role in parasite elimination. *Microbes Infect* 11(10–11):842–849. <https://doi.org/10.1016/j.micinf.2009.05.001>
54. Chaves MM, Sinflorio DA, Thorstenberg ML, Martins MDA, Moreira-Souza ACA, Rangel TP, Silva CLM, Bellio M, Canetti C, Coutinho-Silva R (2019) Non-canonical NLRP3 inflammatory activation and IL-1 $\beta$  signaling are necessary to *L. amazonensis* control mediated by P2X7 receptor and leukotriene B<sub>4</sub>. *PLoS Pathogens* 15(6):e1007887. <https://doi.org/10.1371/journal.ppat.1007887>
55. Thorstenberg ML, Rangel Ferreira MV, Amorim N, Canetti C, Morrone FB, Alves Filho JC, Coutinho-Silva R (2018) Purinergic Cooperation Between P2Y2 and P2X7 Receptors Promote Cutaneous Leishmaniasis Control: Involvement of Pannexin-1 and Leukotrienes. *Front Immunol* 9:1531. <https://doi.org/10.3389/fimmu.2018.01531>
56. Figliuolo VR, Chaves SP, Savio LEB, Thorstenberg MLP, Machado Salles E, Takiya CM, D'Imperio-Lima MR, de Matos Guedes HL, Rossi-Bergmann B, Coutinho-Silva R (2017) The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control. *Purinergic Signal* 13(2):143–152. <https://doi.org/10.1007/s11302-016-9544-1>
57. de Souza MC, de Assis EA, Gomes RS, da Silva M, Ede A, Melo MN, Fietto JL, Afonso LC (2010) The influence of ectonucleotidases on *Leishmania amazonensis* infection and immune response in C57B/6 mice. *Acta Trop* 115(3):262–269. <https://doi.org/10.1016/j.actatropica.2010.04.007>
58. de Almeida Marques-da-Silva E, de Oliveira JC, Figueiredo AB, de Souza Lima Junior D, Carneiro CM, Rangel Fietto JL, Crocco Afonso LC (2008) Extracellular nucleotide metabolism in *Leishmania*: influence of adenosine in the establishment of infection. *Microbes Infect* 10(8):850–857. <https://doi.org/10.1016/j.micinf.2008.04.016>
59. Figueiredo AB, Souza-Testasica MC, Mineo TWP, Afonso LCC (2017) *Leishmania amazonensis*-Induced cAMP Triggered by Adenosine A2B Receptor Is Important to Inhibit Dendritic Cell Activation and Evade Immune Response in Infected Mice. *Front Immunol* 8:849. <https://doi.org/10.3389/fimmu.2017.00849>
60. Tonin AA, Da Silva AS, Ruchel JB, Rezer JF, Camillo G, Faccio L, Franca RT, Leal DB, Duarte MM, Vogel FF, de la Rue ML, Lopes ST (2013) E-NTPDase and E-ADA activities in lymphocytes associated with the immune response of rats experimentally infected with *Toxoplasma gondii*. *Exp Parasitol* 135(2):325–330. <https://doi.org/10.1016/j.exppara.2013.07.014>
61. Tonin AA, Da Silva AS, Casali EA, Silveira SS, Moritz CE, Camillo G, Flores MM, Figuera R, Thome GR, Morsch VM, Schetinger MR, Rue Mde L, Vogel FS, Lopes ST (2014) Influence of infection by *Toxoplasma gondii* on purine levels and E-ADA activity in the brain of mice experimentally infected mice. *Exp Parasitol* 142:51–58. <https://doi.org/10.1016/j.exppara.2014.04.008>
62. Bottari NB, Reichert KP, Fracasso M, Dutra A, Assmann CE, Ulrich H, Schetinger MRC, Morsch VM, Da Silva AS (2020) Neuroprotective role of resveratrol mediated by purinergic signalling in cerebral cortex of mice infected by *Toxoplasma gondii*. *Parasitol Res*. <https://doi.org/10.1007/s00436-020-06795-0>
63. Mahamed DA, Toussaint LE, Bynoe MS (2015) CD73-generated adenosine is critical for immune regulation during *Toxoplasma gondii* infection. *Infect Immun* 83(2):721–729. <https://doi.org/10.1128/IAI.02536-14>
64. Francois V, Shehade H, Acolty V, Preyat N, Delree P, Moser M, Oldenhove G (2015) Intestinal immunopathology is associated with decreased CD73-generated adenosine during lethal infection. *Mucosal Immunol* 8(4):773–784. <https://doi.org/10.1038/mi.2014.108>
65. Mahamed DA, Mills JH, Egan CE, Denkers EY, Bynoe MS (2012) CD73-generated adenosine facilitates *Toxoplasma gondii* differentiation to long-lived tissue cysts in the central nervous system. *Proc Natl Acad Sci U S A* 109(40):16312–16317. <https://doi.org/10.1073/pnas.1205589109>
66. Moreira-Souza ACA, Rangel TP, Silva S, Figliuolo VR, Savio LEB, Schmitz F, Takiya CM, Wyse ATS, Vommaro RC, Coutinho-Silva R (2019) Disruption of Purinergic Receptor P2X7 Signaling Increases Susceptibility to Cerebral

- Toxoplasmosis. *Am J Pathol* 189(4):730–738. <https://doi.org/10.1016/j.ajpath.2019.01.001>
67. Moreira-Souza ACA, Almeida-da-Silva CLC, Rangel TP, Rocha GDC, Bellio M, Zamboni DS, Vommaro RC, Coutinho-Silva R (2017) The P2X7 Receptor Mediates *Toxoplasma gondii* Control in Macrophages through Canonical NLRP3 Inflammasome Activation and Reactive Oxygen Species Production. *Front Immunol* 8:1257. <https://doi.org/10.3389/fimmu.2017.01257>
  68. Correa G, Marques da Silva C, de Abreu Moreira-Souza AC, Vommaro RC, Coutinho-Silva R (2010) Activation of the P2X(7) receptor triggers the elimination of *Toxoplasma gondii* tachyzoites from infected macrophages. *Microbes Infect* 12(6):497–504. <https://doi.org/10.1016/j.micinf.2010.03.004>
  69. Lees MP, Fuller SJ, McLeod R, Boulter NR, Miller CM, Zakrzewski AM, Mui EJ, Witola WH, Coyne JJ, Hargrave AC, Jamieson SE, Blackwell JM, Wiley JS, Smith NC (2010) P2X7 receptor-mediated killing of an intracellular parasite, *Toxoplasma gondii*, by human and murine macrophages. *J Immunol* 184(12):7040–7046. <https://doi.org/10.4049/jimmunol.1000012>
  70. Huang SW, Walker K, Pennock J, Else K, Muller W, Daniels MJ, Pellegrini C, Brough D, Lopez-Castejon G, Cruickshank SM (2017) P2X7 receptor-dependent tuning of gut epithelial responses to infection. *Immunol Cell Biol* 95(2):178–188. <https://doi.org/10.1038/icb.2016.75>
  71. Moreira-Souza AC, Marinho Y, Correa G, Santoro GF, Coutinho CM, Vommaro RC, Coutinho-Silva R (2015) Pyrimidinergic Receptor Activation Controls *Toxoplasma gondii* Infection in Macrophages. *PLoS One* 10(7):e0133502. <https://doi.org/10.1371/journal.pone.0133502>
  72. Moreira-Souza ACA, Coutinho-Silva R (2021) The Complexity of Purinergic Signaling During *Toxoplasma* Infection. *Curr Top Med Chem* 21(3):205–212. <https://doi.org/10.2174/1568026621999201211202533>
  73. Sanmarco LM, Visconti LM, Eberhardt N, Ramello MC, Ponce NE, Spitale NB, Voza ML, Bernardi GA, Gea S, Minguez AR, Aoki MP (2016) IL-6 Improves the Nitric Oxide-Induced Cytotoxic CD8+ T Cell Dysfunction in Human Chagas Disease. *Front Immunol* 7:626. <https://doi.org/10.3389/fimmu.2016.00626>
  74. Sanmarco LM, Eberhardt N, Bergero G, Quebrada Palacio LP, Adami PM, Visconti LM, Minguez AR, Hernandez-Vasquez Y, Carrera Silva EA, Morelli L, Postan M, Aoki MP (2019) Monocyte glycolysis determines CD8+ T cell functionality in human Chagas disease. *JCI Insight* 4(18). <https://doi.org/10.1172/jci.insight.123490>
  75. Eberhardt N, Sanmarco LM, Bergero G, Favalaro RR, Vigliano C, Aoki MP (2020) HIF-1 $\alpha$  and CD73 expression in cardiac leukocytes correlates with the severity of myocarditis in end-stage Chagas disease patients. *J Leukoc Biol*. <https://doi.org/10.1002/JLB.4MA0420-125R>
  76. Souza VD, Dos Santos JT, Cabral FL, Barbisan F, Azevedo MI, Dias Carli LF, de Avila BS, Dos Santos Jaques JA, Rosa Leal DB (2017) Evaluation of P2X7 receptor expression in peripheral lymphocytes and immune profile from patients with indeterminate form of Chagas disease. *Microb Pathog* 104:32–38. <https://doi.org/10.1016/j.micpath.2017.01.002>
  77. do Carmo GM, Doleski PH, de Sa MF, Grando TH, Bottari NB, Leal DB, Gressler LT, Henker LC, Mendes RE, Monteiro SG, Da Silva AS (2017) Purinergic enzymatic activities in lymphocytes and cardiomyocytes of mice acutely infected by *Trypanosoma cruzi* modulating the inflammatory responses. *Exp Parasitol* 175:44–50. <https://doi.org/10.1016/j.exppara.2017.02.002>
  78. Grand TH, Baldissera MD, Do Carmo G, Oliveira CB, Santi ET, Doleski PH, Leal DBR, Stefani LM, Mendes RE, Da Silva AS, Monteiro SG (2018) Ecto-enzymes activities in splenic lymphocytes of mice experimentally infected by *Trypanosoma cruzi* and treated with specific avian immunoglobulins: an attempt to improve the immune response. *Mol Cell Biochem* 448(1–2):9–15. <https://doi.org/10.1007/s11010-018-3308-x>
  79. Eberhardt N, Sanmarco LM, Bergero G, Theumer MG, Garcia MC, Ponce NE, Cano RC, Aoki MP (2020) Deficiency of CD73 activity promotes protective cardiac immunity against *Trypanosoma cruzi* infection but permissive environment in visceral adipose tissue. *Biochim Biophys Acta* 1866(3):165592. <https://doi.org/10.1016/j.bbadis.2019.165592>
  80. Ponce NE, Sanmarco LM, Eberhardt N, Garcia MC, Rivarola HW, Cano RC, Aoki MP (2016) CD73 Inhibition Shifts Cardiac Macrophage Polarization toward a Microbicidal Phenotype and Ameliorates the Outcome of Experimental Chagas Cardiomyopathy. *J Immunol* 197(3):814–823. <https://doi.org/10.4049/jimmunol.1600371>
  81. Santos RF, Possa MA, Bastos MS, Guedes PM, Almeida MR, Demarco R, Verjovski-Almeida S, Bahia MT, Fietto JL (2009) Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on *Trypanosoma cruzi* infectivity and virulence. *PLoS Negl Trop Dis* 3(3):e387. <https://doi.org/10.1371/journal.pntd.0000387>
  82. do Carmo GM, Doleski PH, de Sa MF, Grando TH, Azevedo MI, Manzoni AG, Leal DBR, Gressler LT, Henker LC, Mendes RE, Baldissera MD, Monteiro SG, Stefani LM, Da Silva AS (2017) Treatment with 3'-deoxyadenosine and deoxycytosine in mice infected by *Trypanosoma cruzi* and its side effect on purinergic enzymes. *Microb Pathog* 113:51–56. <https://doi.org/10.1016/j.micpath.2017.10.030>
  83. Borges-Pereira L, Meissner KA, Wrenger C, Garcia CRS (2017) Plasmodium falciparum GFP-E-NTPase expression at the intraerythrocytic stages and its inhibition blocks the development of the human malaria parasite. *Purinergic Signal* 13(3):267–277. <https://doi.org/10.1007/s11302-017-9557-4>
  84. Levano-Garcia J, Dluzewski AR, Markus RP, Garcia CR (2010) Purinergic signalling is involved in the malaria parasite *Plasmodium falciparum* invasion to red blood cells. *Purinergic Signal* 6(4):365–372. <https://doi.org/10.1007/s11302-010-9202-y>
  85. Huber SM (2012) Purinoceptor signaling in malaria-infected erythrocytes. *Microbes Infect* 14(10):779–786. <https://doi.org/10.1016/j.micinf.2012.04.009>
  86. Marin-Garcia P, Sanchez-Nogueiro J, Diez A, Leon-Otegui M, Linares M, Garcia-Palencia P, Bautista JM, Miras-Portugal MT (2009) Altered nucleotide receptor expression in a murine model of cerebral malaria. *J Infect Dis* 200(8):1279–1288. <https://doi.org/10.1086/605896>
  87. Salles EM, Menezes MN, Siqueira R, Borges da Silva H, Amaral EP, Castillo-Mendez SI, Cunha I, Cassado ADA, Vieira FS, Olivieri DN, Tadokoro CE, Alvarez JM, Coutinho-Silva R, D'Imperio-Lima MR (2017) P2X7 receptor drives Th1 cell differentiation and controls the follicular helper T cell population to protect against *Plasmodium chabaudi* malaria. *PLoS Pathog* 13(8):e1006595. <https://doi.org/10.1371/journal.ppat.1006595>
  88. Abel A, Steeg C, Aminkiah F, Addai-Mensah O, Addo M, Gagliani N, Casar C, Yar DD, Owusu-Dabo E, Jacobs T, Mackroth MS (2018) Differential expression pattern of co-inhibitory molecules on CD4(+) T cells in uncomplicated versus complicated malaria. *Sci Rep* 8(1):4789. <https://doi.org/10.1038/s41598-018-22659-1>
  89. Allen JE, Maizels RM (2011) Diversity and dialogue in immunity to helminths. *Nat Rev Immunol* 11(6):375–388. <https://doi.org/10.1038/nri2992>
  90. de Moraes J, Geary TG (2020) FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis? *Trends Parasitol* 36(7):573–575. <https://doi.org/10.1016/j.pt.2020.04.005>
  91. Patel N, Wu W, Mishra PK, Chen F, Millman A, Csoka B, Koscsó B, Eltzschig HK, Hasko G, Gause WC (2014) A2B adenosine receptor induces protective antihelminth type 2



- immune responses. *Cell Host Microbe* 15(3):339–350. <https://doi.org/10.1016/j.chom.2014.02.001>
92. Lima NF, Goncalves-Lopes RM, Kruize YCM, Yazdanbakhsh M, Ferreira MU (2018) CD39 and immune regulation in a chronic helminth infection: The puzzling case of *Mansonella ozzardi*. *PLoS Negl Trop Dis* 12(3):e0006327. <https://doi.org/10.1371/journal.pntd.0006327>
  93. Oliveira SD, Oliveira NF, Meyer-Fernandes JR, Savio LE, Ornelas FG, Ferreira ZS, Coutinho-Silva R, Silva CL (2016) Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y1 receptors. *Vascul Pharmacol* 82:66–72. <https://doi.org/10.1016/j.vph.2016.02.005>
  94. Oliveira NF, Silva CLM (2021) Unveiling the Potential of Purinergic Signaling in Schistosomiasis Treatment. *Curr Top Med Chem* 21(3):193–204. <https://doi.org/10.2174/1568026620666200924115113>
  95. Doleski PH, Mendes RE, Leal DB, Bottari NB, Piva MM, Da Silva ES, Gabriel ME, Lucca NJ, Schwertz CI, Giacomini P, Morsch VM, Schetinger MR, Baldissera MD, Da Silva AS (2016) Seric and hepatic NTPDase and 5' nucleotidase activities of rats experimentally infected by *Fasciola hepatica*. *Parasitology* 143(5):551–556. <https://doi.org/10.1017/S0031182015001882>
  96. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, Goletti D (2009) Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. *Clin Exp Immunol* 156(3):463–470. <https://doi.org/10.1111/j.1365-2249.2009.03908.x>
  97. Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA (2013) CD39 is involved in mediating suppression by *Mycobacterium bovis* BCG-activated human CD8(+) CD39(+) regulatory T cells. *Eur J Immunol* 43(7):1925–1932. <https://doi.org/10.1002/eji.201243286>
  98. Petit-Jentreau L, Jouvion G, Charles P, Majlessi L, Gicquel B, Tailleux L (2015) Ecto-5'-Nucleotidase (CD73) Deficiency in *Mycobacterium tuberculosis*-Infected Mice Enhances Neutrophil Recruitment. *Infect Immun* 83(9):3666–3674. <https://doi.org/10.1128/IAI.00418-15>
  99. Amaral EP, Ribeiro SC, Lanes VR, Almeida FM, de Andrade MR, Bomfim CC, Salles EM, Bortoluci KR, Coutinho-Silva R, Hirata MH, Alvarez JM, Lasunskaja EB, D'Imperio-Lima MR (2014) Pulmonary infection with hypervirulent *Mycobacteria* reveals a crucial role for the P2X7 receptor in aggressive forms of tuberculosis. *PLoS Pathog* 10(7):e1004188. <https://doi.org/10.1371/journal.ppat.1004188>
  100. Santiago-Carvalho I, de Almeida-Santos G, Bomfim CCB, de Souza PC, Silva J, de Melo BMS, Amaral EP, Cione MVP, Lasunskaja E, Hirata MH, Alves-Filho JCF, Nakaya HI, Alvarez JM, D'Imperio Lima MR (2021) P2x7 Receptor Signaling Blockade Reduces Lung Inflammation and Necrosis During Severe Experimental Tuberculosis. *Front Cell Infect Microbiol* 11:672472. <https://doi.org/10.3389/fcimb.2021.672472>
  101. Bomfim CCB, Amaral EP, Cassado ADA, Salles EM, do Nascimento RS, Lasunskaja E, Hirata MH, Alvarez JM, D'Imperio-Lima MR, (2017) P2X7 Receptor in Bone Marrow-Derived Cells Aggravates Tuberculosis Caused by Hypervirulent *Mycobacterium bovis*. *Front Immunol* 8:435. <https://doi.org/10.3389/fimmu.2017.00435>
  102. Santos AA Jr, Rodrigues-Junior V, Zanin RF, Borges TJ, Bonorino C, Coutinho-Silva R, Takyia CM, Santos DS, Campos MM, Morrone FB (2013) Implication of purinergic P2X7 receptor in *M. tuberculosis* infection and host interaction mechanisms: a mouse model study. *Immunobiology* 218(8):1104–1112. <https://doi.org/10.1016/j.imbio.2013.03.003>
  103. Matty MA, Knudsen DR, Walton EM, Beerman RW, Cronan MR, Pyle CJ, Hernandez RE, Tobin DM (2019) Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection. *eLife* 8. <https://doi.org/10.7554/eLife.39123>
  104. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, Marks GB, Wiley JS, Britton WJ (2007) A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. *Am J Respir Crit Care Med* 175(4):360–366. <https://doi.org/10.1164/rccm.200607-970OC>
  105. Karmakar M, Katsnelson MA, Dubyak GR, Pearlman E (2016) Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP. *Nat Commun* 7:10555. <https://doi.org/10.1038/ncomms10555>
  106. Liu YH, Chang YC, Chen LK, Su PA, Ko WC, Tsai YS, Chen YH, Lai HC, Wu CY, Hung YP, Tsai PJ (2018) The ATP-P2X7 Signaling Axis Is an Essential Sentinel for Intracellular *Clostridium difficile* Pathogen-Induced Inflammasome Activation. *Front Cell Infect Microbiol* 8:84. <https://doi.org/10.3389/fcimb.2018.00084>
  107. Dubois-Colas N, Petit-Jentreau L, Barreiro LB, Durand S, Soubigou G, Lecoite C, Klibi J, Rezai K, Lokiec F, Coppee JY, Gicquel B, Tailleux L (2014) Extracellular adenosine triphosphate affects the response of human macrophages infected with *Mycobacterium tuberculosis*. *J Infect Dis* 210(5):824–833. <https://doi.org/10.1093/infdis/jiu135>
  108. Amaral EP, Machado de Salles E, Barbosa Bomfim CC, Salgado RM, Almeida FM, de Souza PC, Alvarez JM, Hirata MH, Lasunskaja EB, D'Imperio-Lima MR (2019) Inhibiting Adenosine Receptor Signaling Promotes Accumulation of Effector CD4+ T Cells in the Lung Parenchyma During Severe Tuberculosis. *J Infect Dis* 219(6):964–974. <https://doi.org/10.1093/infdis/jiy586>
  109. Olotu C, Lehmsiek F, Koch B, Kiefmann M, Riegel AK, Hammerschmidt S, Kiefmann R (2019) Streptococcus pneumoniae inhibits purinergic signaling and promotes purinergic receptor P2Y2 internalization in alveolar epithelial cells. *J Biol Chem* 294(34):12795–12806. <https://doi.org/10.1074/jbc.RA118.007236>
  110. Bou Ghanem EN, Clark S, Roggensack SE, McIver SR, Alcaide P, Hayden PG, Leong JM (2015) Extracellular Adenosine Protects against *Streptococcus pneumoniae* Lung Infection by Regulating Pulmonary Neutrophil Recruitment. *PLoS Pathog* 11(8):e1005126. <https://doi.org/10.1371/journal.ppat.1005126>
  111. Siwapornchai N, Lee JN, Tchalla EYI, Bhalla M, Yeoh JH, Roggensack SE, Leong JM, Bou Ghanem EN (2020) Extracellular adenosine enhances the ability of PMNs to kill *Streptococcus pneumoniae* by inhibiting IL-10 production. *J Leukoc Biol*. <https://doi.org/10.1002/JLB.4MA0120-115RR>
  112. Bhalla M, Hui Yeoh J, Lamneck C, Herring SE, Tchalla EYI, Heinzinger LR, Leong JM, Bou Ghanem EN (2020) A1 adenosine receptor signaling reduces *Streptococcus pneumoniae* adherence to pulmonary epithelial cells by targeting expression of platelet-activating factor receptor. *Cell Microbiol* 22(2):e13141. <https://doi.org/10.1111/cmi.13141>
  113. Allard D, Charlebois R, Gilbert L, Stagg J, Chrobak P (2018) CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. *PLoS One* 13(1):e0191973. <https://doi.org/10.1371/journal.pone.0191973>
  114. Barletta KE, Cagnina RE, Burdick MD, Linden J, Mehrad B (2012) Adenosine A(2B) receptor deficiency promotes host defenses against gram-negative bacterial pneumonia. *Am J Respir Crit Care Med* 186(10):1044–1050. <https://doi.org/10.1164/rccm.201204-0622OC>
  115. Inami A, Kiyono H, Kurashima Y (2018) ATP as a Pathophysiologic Mediator of Bacteria-Host Crosstalk in the Gastrointestinal Tract. *Int J Mol Sci* 19(8). <https://doi.org/10.3390/jms19082371>

116. Kao DJ, Saeedi BJ, Kitzenberg D, Burney KM, Dobrinskikh E, Battista KD, Vazquez-Torres A, Colgan SP, Kominsky DJ (2017) Intestinal Epithelial Ecto-5'-Nucleotidase (CD73) Regulates Intestinal Colonization and Infection by Nontyphoidal Salmonella. *Infect Immun* 85(10). <https://doi.org/10.1128/IAI.01022-16>
117. Alam MS, Kuo JL, Ernst PB, Derr-Castillo V, Pereira M, Gaines D, Costales M, Bigley E, Williams K (2014) Ecto-5'-nucleotidase (CD73) regulates host inflammatory responses and exacerbates murine salmonellosis. *Sci Rep* 4:4486. <https://doi.org/10.1038/srep04486>
118. Costales MG, Alam MS, Cavanaugh C, Williams KM (2018) Extracellular adenosine produced by ecto-5'-nucleotidase (CD73) regulates macrophage pro-inflammatory responses, nitric oxide production, and favors Salmonella persistence. *Nitric Oxide Biol Chem* 72:7–15. <https://doi.org/10.1016/j.niox.2017.11.001>
119. Proietti M, Perruzza L, Scribano D, Pellegrini G, D'Antuono R, Strati F, Raffaelli M, Gonzalez SF, Thelen M, Hardt WD, Slack E, Nicoletti M, Grassi F (2019) ATP released by intestinal bacteria limits the generation of protective IgA against enteropathogens. *Nat Commun* 10(1):250. <https://doi.org/10.1038/s41467-018-08156-z>
120. Csoka B, Nemeth ZH, Szabo I, Davies DL, Varga ZV, Paloczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, Pacher P, Hasko G (2018) Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. *JCI Insight* 3(11). <https://doi.org/10.1172/jci.insight.99431>
121. Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukasev D, Buras JA, Remick DG, Sitkovsky M (2011) A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. *J Immunol* 186(4):2444–2453. <https://doi.org/10.4049/jimmunol.1001567>
122. Nascimento DC, Viacava PR, Ferreira RG, Damaceno MA, Pinerros AR, Melo PH, Donate PB, Toller-Kawahisa JE, Zoppi D, Veras FP, Peres RS, Menezes-Silva L, Caetite D, Oliveira AER, Castro IMS, Kauffenstein G, Nakaya HI, Borges MC, Zamboni DS, Fonseca DM, Paschoal JAR, Cunha TM, Quesniaux V, Linden J, Cunha FQ, Ryffel B, Alves-Filho JC (2021) Sepsis expands a CD39(+) plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. *Immunity* 54(9):2024–2041 e2028. <https://doi.org/10.1016/j.immuni.2021.08.005>
123. Csoka B, Nemeth ZH, Toro G, Idzko M, Zech A, Koscsó B, Spolarics Z, Antonioli L, Cseri K, Erdelyi K, Pacher P, Hasko G (2015) Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. *FASEB J* 29(9):3626–3637. <https://doi.org/10.1096/fj.15-272450>
124. Lee AH, Ledderose C, Li X, Slubowski CJ, Sueyoshi K, Staudenmaier L, Bao Y, Zhang J, Junger WG (2018) Adenosine Triphosphate Release is Required for Toll-Like Receptor-Induced Monocyte/Macrophage Activation, Inflammasome Signaling, Interleukin-1beta Production, and the Host Immune Response to Infection. *Crit Care Med* 46(12):e1183–e1189. <https://doi.org/10.1097/CCM.0000000000003446>
125. Zhang X, Qin J, Zou J, Lv Z, Tan B, Shi J, Zhao Y, Ren H, Liu M, Qian M, Du B (2018) Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling. *Cell Mol Immunol* 15(1):58–73. <https://doi.org/10.1038/cmi.2016.56>
126. Greve AS, Skals M, Fagerberg SK, Tonnus W, Ellermann-Erikson S, Evans RJ, Linkermann A, Praetorius HA (2017) P2X1, P2X4, and P2X7 Receptor Knock Out Mice Expose Differential Outcome of Sepsis Induced by alpha-Haemolysin Producing Escherichia coli. *Front Cell Infect Microbiol* 7:113. <https://doi.org/10.3389/fcimb.2017.00113>
127. Skals M, Greve AS, Fagerberg SK, Johnsen N, Christensen MG, Praetorius HA (2019) P2X1 receptor blockers reduce the number of circulating thrombocytes and the overall survival of urosepsis with haemolysin-producing Escherichia coli. *Purinergic Signal* 15(2):265–276. <https://doi.org/10.1007/s11302-019-09658-1>
128. Fagerberg SK, Jakobsen MR, Skals M, Praetorius HA (2016) Inhibition of P2X Receptors Protects Human Monocytes against Damage by Leukotoxin from Aggregatibacter actinomycetemcomitans and alpha-Hemolysin from Escherichia coli. *Infect Immun* 84(11):3114–3130. <https://doi.org/10.1128/IAI.00674-16>
129. Perez-Flores G, Hernandez-Silva C, Gutierrez-Escobedo G, De Las PA, Castano I, Arreola J, Perez-Cornejo P (2016) P2X7 from j774 murine macrophages acts as a scavenger receptor for bacteria but not yeast. *Biochem Biophys Res Commun* 481(1–2):19–24. <https://doi.org/10.1016/j.bbrc.2016.11.027>
130. Tang X, Basavarajappa D, Haeggstrom JZ, Wan M (2015) P2X7 Receptor Regulates Internalization of Antimicrobial Peptide LL-37 by Human Macrophages That Promotes Intracellular Pathogen Clearance. *J Immunol* 195(3):1191–1201. <https://doi.org/10.4049/jimmunol.1402845>
131. Schwiering M, Husmann M, Hellmann N (2017) P2X-Receptor Antagonists Inhibit the Interaction of S. aureus Hemolysin A with Membranes. *Toxins* 9(10). <https://doi.org/10.3390/toxins9100332>
132. Nagahama M, Seike S, Shirai H, Takagishi T, Kobayashi K, Takehara M (1850) Sakurai J (2015) Role of P2X7 receptor in Clostridium perfringens beta-toxin-mediated cellular injury. *Biochem Biophys Acta* 11:2159–2167. <https://doi.org/10.1016/j.bbagen.2015.08.011>
133. Thammaravongsa V, Kern JW, Missiakas DM, Schneewind O (2009) Staphylococcus aureus synthesizes adenosine to escape host immune responses. *J Exp Med* 206(11):2417–2427. <https://doi.org/10.1084/jem.20090097>
134. Paoletti A, Raza SQ, Voisin L, Law F, Pipoli da Fonseca J, Caillet M, Kroemer G, Perfettini JL (2012) Multifaceted roles of purinergic receptors in viral infection. *Microbes Infect* 14(14):1278–1283. <https://doi.org/10.1016/j.micinf.2012.05.010>
135. Pacheco PA, Faria RX, Ferreira LG, Paixao IC (2014) Putative roles of purinergic signaling in human immunodeficiency virus-1 infection. *Biol Direct* 9:21. <https://doi.org/10.1186/1745-6150-9-21>
136. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, Hue S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Levy Y (2011) CD39/adenosine pathway is involved in AIDS progression. *PLoS Pathog* 7(7):e1002110. <https://doi.org/10.1371/journal.ppat.1002110>
137. Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kok A, Routy JP, Tremblay A, Sevigny J, Lelievre JD, Levy Y (2013) Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. *PLoS Pathog* 9(4):e1003319. <https://doi.org/10.1371/journal.ppat.1003319>
138. Song JW, Huang HH, Zhang C, Yang HG, Zhang JY, Xu RN, Jin L, Shi M, Wang FS, Jiao YM (2019) Expression of CD39 Is Correlated With HIV DNA Levels in Naive Tregs in Chronically Infected ART Naive Patients. *Front Immunol* 10:2465. <https://doi.org/10.3389/fimmu.2019.02465>
139. Dierks P, Wroblewski R, Eberhard JM, Martrus G, Degen O, Hertling S, Schmiedel S, Lunemann S, Hufner A, Lohse AW, Altfeld M, van Lunzen J, Schulze Zur Wiesch J (2017) Brief Report: Increased Frequency of CD39+ CD56bright Natural Killer Cells in HIV-1 Infection Correlates With Immune Activation and Disease Progression. *J Acquir Immune Defic Syndr* 74(4):467–472. <https://doi.org/10.1097/QAI.0000000000001266>

140. Burton CT, Westrop SJ, Eccles-James I, Boasso A, Nelson MR, Bower M, Imami N (2011) Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function. *Clin Exp Immunol* 166(2):191–200. <https://doi.org/10.1111/j.1365-2249.2011.04451.x>
141. Schuler PJ, Macatangay BJ, Saze Z, Jackson EK, Riddler SA, Buchanan WG, Hilldorfer BB, Mellors JW, Whiteside TL, Rinaldo CR (2013) CD4(+)CD73(+) T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. *AIDS* 27(10):1545–1555. <https://doi.org/10.1097/QAD.0b013e328360c7f3>
142. Toth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch P, Degen O, Lohse AW, Eiermann T, Fatkenheuer G, Meyer-Olson D, Bockhorn M, Hauber J, van Lunzen J, Schulze Zur Wiesch J (2013) Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. *J Leukoc Biol* 94(4):551–561. <https://doi.org/10.1189/jlb.0113018>
143. Carriere M, Lacabaratz C, Kok A, Benne C, Jenabian MA, Casartelli N, Hue S, Hocqueloux L, Lelievre JD, Levy Y (2014) HIV “elite controllers” are characterized by a high frequency of memory CD8+ CD73+ T cells involved in the antigen-specific CD8+ T-cell response. *J Infect Dis* 209(9):1321–1330. <https://doi.org/10.1093/infdis/jit643>
144. Kim ES, Ackermann C, Toth I, Dierks P, Eberhard JM, Wroblewski R, Scherg F, Geyer M, Schmidt RE, Beisel C, Bockhorn M, Haag F, van Lunzen J, Schulze Zur Wiesch J (2017) Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. *J Leukoc Biol* 101(5):1263–1271. <https://doi.org/10.1189/jlb.5A0816-346R>
145. Casanova V, Naval-Macabuhay I, Massanella M, Rodriguez-Garcia M, Blanco J, Gatell JM, Garcia F, Gallart T, Lluís C, Mallol J, Franco R, Climent N, McCormick PJ (2012) Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. *PLoS One* 7(12):e51287. <https://doi.org/10.1371/journal.pone.0051287>
146. Naval-Macabuhay I, Casanova V, Navarro G, Garcia F, Leon A, Miralles L, Rovira C, Martinez-Navio JM, Gallart T, Mallol J, Gatell JM, Lluís C, Franco R, McCormick PJ, Climent N (2016) Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. *J Leukoc Biol* 99(2):349–359. <https://doi.org/10.1189/jlb.3A1214-580RR>
147. Barat C, Gilbert C, Imbeault M, Tremblay MJ (2008) Extracellular ATP reduces HIV-1 transfer from immature dendritic cells to CD4+ T lymphocytes. *Retrovirology* 5:30. <https://doi.org/10.1186/1742-4690-5-30>
148. Tardif V, Muir R, Cubas R, Chakhtoura M, Wilkinson P, Metcalf T, Herro R, Haddad EK (2019) Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV. *Nat Commun* 10(1):823. <https://doi.org/10.1038/s41467-019-08801-1>
149. Hixson EA, Borker PV, Jackson EK, Macatangay BJ (2021) The Adenosine Pathway and Human Immunodeficiency Virus-Associated Inflammation. *Open Forum Infect Dis* 8(9):ofa396. <https://doi.org/10.1093/ofid/ofab396>
150. Orellana JA, Velasquez S, Williams DW, Saez JC, Berman JW, Eugenin EA (2013) Pannexin1 hemichannels are critical for HIV infection of human primary CD4+ T lymphocytes. *J Leukoc Biol* 94(3):399–407. <https://doi.org/10.1189/jlb.0512249>
151. Seror C, Melki MT, Subra F, Raza SQ, Bras M, Saidi H, Nardacci R, Voisin L, Paoletti A, Law F, Martins I, Amendola A, Abdul-Sater AA, Ciccocanti F, Delelis O, Niedergang F, Thierry S, Said-Sadier N, Lamaze C, Metivier D, Estaquier J, Fimia GM, Falasca L, Casetti R, Modjtahedi N, Kanellopoulos J, Mouscadet JF, Ojcius DM, Piacentini M, Gougeon ML, Kroemer G, Perfettini JL (2011) Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. *J Exp Med* 208(9):1823–1834. <https://doi.org/10.1084/jem.20101805>
152. Freeman TL, Swartz TH (2020) Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion. *Viruses* 12(3). <https://doi.org/10.3390/v12030290>
153. Hazleton JE, Berman JW, Eugenin EA (2012) Purinergic receptors are required for HIV-1 infection of primary human macrophages. *J Immunol* 188(9):4488–4495. <https://doi.org/10.4049/jimmunol.1102482>
154. Schachter J, Delgado KV, Barreto-de-Souza V, Bou-Habib DC, Persechini PM, Meyer-Fernandes JR (2015) Inhibition of ecto-ATPase activities impairs HIV-1 infection of macrophages. *Immunobiology* 220(5):589–596. <https://doi.org/10.1016/j.imbio.2014.12.004>
155. Soare AY, Durham ND, Gopal R, Tweel B, Hoffman KW, Brown JA, O'Brien M, Bhardwaj N, Lim JK, Chen BK, Swartz TH (2019) P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1beta in a Human Tonsil Explant Model. *J Virol* 93(1). <https://doi.org/10.1128/JVI.01186-18>
156. Giroud C, Marin M, Hammonds J, Spearman P, Melikyan GB (2015) P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. *J Virol* 89(18):9368–9382. <https://doi.org/10.1128/JVI.01178-15>
157. Swartz TH, Esposito AM, Durham ND, Hartmann BM, Chen BK (2014) P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection. *J Virol* 88(19):11504–11515. <https://doi.org/10.1128/JVI.01158-14>
158. Zhang C, He H, Wang L, Zhang N, Huang H, Xiong Q, Yan Y, Wu N, Ren H, Han H, Liu M, Qian M, Du B (2017) Virus-Triggered ATP Release Limits Viral Replication through Facilitating IFN-beta Production in a P2X7-Dependent Manner. *J Immunol* 199(4):1372–1381. <https://doi.org/10.4049/jimmunol.1700187>
159. Lee BH, Hwang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J (2012) Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. *PLoS One* 7(4):e35812. <https://doi.org/10.1371/journal.pone.0035812>
160. Leyva-Grado VH, Ermler ME, Schotsaert M, Gonzalez MG, Gillespie V, Lim JK, Garcia-Sastre A (2017) Contribution of the Purinergic Receptor P2X7 to Development of Lung Immunopathology during Influenza Virus Infection. *mBio* 8(2). <https://doi.org/10.1128/mBio.00229-17>
161. Vanderstocken G, Van de Paar E, Robaye B, di Pietrantonio L, Bondue B, Boeynaems JM, Desmecht D, Communi D (2012) Protective role of P2Y2 receptor against lung infection induced by pneumonia virus of mice. *PLoS One* 7(11):e50385. <https://doi.org/10.1371/journal.pone.0050385>
162. Aeffner F, Woods PS, Davis IC (2015) Ecto-5'-nucleotidase CD73 modulates the innate immune response to influenza infection but is not required for development of influenza-induced acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 309(11):L1313–L1322. <https://doi.org/10.1152/ajplung.00130.2015>

163. Woods PS, Doolittle LM, Hickman-Davis JM, Davis IC (2018) ATP catabolism by tissue nonspecific alkaline phosphatase contributes to development of ARDS in influenza-infected mice. *Am J Physiol Lung Cell Mol Physiol* 314(1):L83–L92. <https://doi.org/10.1152/ajplung.00149.2017>
164. Ahmadi P, Hartjen P, Kohsar M, Kummer S, Schmiedel S, Bockmann JH, Fathi A, Huber S, Haag F, Schulze Zur Wiesch J (2020) Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes. *Cells* 9(8). <https://doi.org/10.3390/cells9081750>
165. Ribeiro DE, Oliveira-Giacomelli A, Glaser T, Arnaud-Sampaio VF, Andrejew R, Dieckmann L, Baranova J, Lameu C, Ratajczak MZ, Ulrich H (2021) Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. *Mol Psychiatry* 26(4):1044–1059. <https://doi.org/10.1038/s41380-020-00965-3>
166. Franciosi MLM, Lima MDM, Schetinger MRC, Cardoso AM (2021) Possible role of purinergic signaling in COVID-19. *Mol Cell Biochem* 476(8):2891–2898. <https://doi.org/10.1007/s11010-021-04130-4>
167. Simoes JLB, Bagatini MD (2021) Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barre Syndrome. *J Neuroimmune Pharmacol* 16(1):48–58. <https://doi.org/10.1007/s11481-020-09980-1>
168. Corrêa G, Lindenberg C de A, Fernandes-Santos C, Gandini M, Paiva FP, Coutinho-Silva R, Kubelka CF (2016) The purinergic receptor P2X7 role in control of Dengue virus-2 infection and cytokine/chemokine production in infected human monocytes. *Immunobiology* 221(7):794–802. <https://doi.org/10.1016/j.imbio.2016.02.003>
169. Tsai CY, Liang KH, Gunalan MG, Li N, Lim DS, Fisher DA, MacAry PA, Leo YS, Wong SC, Puan KJ, Wong SB (2015) Type I IFNs and IL-18 regulate the antiviral response of primary human gammadelta T cells against dendritic cells infected with Dengue virus. *J Immunol* 194(8):3890–3900. <https://doi.org/10.4049/jimmunol.1303343>
170. Patkar C, Giaya K, Libraty DH (2013) Dengue virus type 2 modulates endothelial barrier function through CD73. *Am J Trop Med Hyg* 88(1):89–94. <https://doi.org/10.4269/ajtmh.2012.12-0474>
171. Taylor JM, Han Z (2010) Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. *PLoS One* 5(12):e15784. <https://doi.org/10.1371/journal.pone.0015784>
172. Ashraf W, Manzoor S, Ashraf J, Ahmed QL, Khalid M, Tariq M, Imran M, Aziz H (2013) Transcript analysis of P2X receptors in PBMCs of chronic HCV patients: an insight into antiviral treatment response and HCV-induced pathogenesis. *Viral Immunol* 26(5):343–350. <https://doi.org/10.1089/vim.2013.0044>
173. Manzoor S, Akhtar U, Naseem S, Khalid M, Mazhar M, Parvaiz F, Khaliq S (2016) Ionotropic Purinergic Receptors P2X4 and P2X7: Proviral or Antiviral? An Insight into P2X Receptor Signaling and Hepatitis C Virus Infection. *Viral Immunol* 29(7):401–408. <https://doi.org/10.1089/vim.2016.0008>
174. Khalid M, Manzoor S, Ahmad H, Asif A, Bangash TA, Latif A, Jaleel S (2018) Purinoceptor expression in hepatocellular virus (HCV)-induced and non-HCV hepatocellular carcinoma: an insight into the proviral role of the P2X4 receptor. *Mol Biol Rep* 45(6):2625–2630. <https://doi.org/10.1007/s11033-018-4432-0>
175. Tang Y, Jiang L, Zheng Y, Ni B, Wu Y (2012) Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection. *BMC Immunol* 13:17. <https://doi.org/10.1186/1471-2172-13-17>
176. Zoppellaro C, Bin A, Brun P, Banzato S, Macchi V, Castagliuolo I, Giron MC (2013) Adenosine-mediated enteric neuromuscular function is affected during herpes simplex virus type 1 infection of rat enteric nervous system. *PLoS One* 8(8):e72648. <https://doi.org/10.1371/journal.pone.0072648>
177. Kan Y, Okabayashi T, Yokota S, Yamamoto S, Fujii N, Yamashita T (2012) Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. *J Virol* 86(19):10338–10346. <https://doi.org/10.1128/JVI.01196-12>
178. Chen S, Shenk T, Nogalski MT (2019) P2Y2 purinergic receptor modulates virus yield, calcium homeostasis, and cell motility in human cytomegalovirus-infected cells. *Proc Natl Acad Sci U S A* 116(38):18971–18982. <https://doi.org/10.1073/pnas.1907562116>
179. Choi SJ, Ryu E, Lee S, Huh S, Shin YS, Kang BW, Kim JG, Cho H, Kang H (2019) Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma. *Int J Mol Sci* 20(6). <https://doi.org/10.3390/ijms20061286>
180. Yang YC, Chang TY, Chen TC, Lin WS, Chang SC, Lee YJ (2016) Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. *Oncotarget* 7(50):82798–82803. <https://doi.org/10.18632/oncotarget.12636>
181. Antonioli L, Blandizzi C, Pacher P, Hasko G (2019) The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. *Pharmacol Rev* 71(3):345–382. <https://doi.org/10.1124/pr.117.014878>
182. Savio LEB, Coutinho-Silva R (2016) Purinergic signaling in infection and autoimmune disease. *Biomed J* 39(5):304–305. <https://doi.org/10.1016/j.bj.2016.09.002>
183. Allard B, Longhi MS, Robson SC, Stagg J (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunol Rev* 276(1):121–144. <https://doi.org/10.1111/immr.12528>
184. Sek K, Molck C, Stewart GD, Kats L, Darcy PK, Beavis PA (2018) Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. *Int J Mol Sci* 19(12). <https://doi.org/10.3390/ijms19123837>
185. Burnstock G (2017) Purinergic Signalling: Therapeutic Developments. *Front Pharmacol* 8:661. <https://doi.org/10.3389/fphar.2017.00661>
186. Burnstock G (2018) The therapeutic potential of purinergic signalling. *Biochem Pharmacol* 151:157–165. <https://doi.org/10.1016/j.bcp.2017.07.016>
187. Azambuja JH, Ludwig N, Braganhol E, Whiteside TL (2019) Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity. *Int J Mol Sci* 20(22). <https://doi.org/10.3390/ijms20225698>

188. Kumar V, Sharma A (2009) Adenosine: an endogenous modulator of innate immune system with therapeutic potential. *Eur J Pharmacol* 616(1–3):7–15. <https://doi.org/10.1016/j.ejphar.2009.05.005>
189. Pacheco PAF, Dantas LP, Ferreira LGB, Faria RX (2018) Purinergic receptors and neglected tropical diseases: why ignore purinergic signaling in the search for new molecular targets? *J Bioenergy Biomembr* 50(4):307–313. <https://doi.org/10.1007/s10863-018-9761-0>
190. da Silva W, da Rocha TN, de Melo AJ, da Silva VHF, de Souza ACA, Ribeiro IC, de Oliveira TA, de Souza LA, Andrade LKR, de Moraes JVB, Diogo MA, de Castro RB, Poletto MD, Afonso LCC, Fietto JLR (2021) ENTPDases from Pathogenic Trypanosomatids and Purinergic Signaling: Shedding Light towards Biotechnological Applications. *Curr Top Med Chem* 21(3):213–226. <https://doi.org/10.2174/1568026620666201005125146>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Natalia Eberhardt, Ph.D.** completed her Ph.D. in immunology from the University of Cordoba, Argentina, in 2019. Her doctoral work focused on understanding the regulation of cardiac immune response by the purinergic system and its contribution to Chagas cardiomyopathy development. She joined the Giannarelli Lab (NYU School of Medicine, NYC) as a postdoctoral fellow in 2020. Her current project includes investigating immune mechanisms that finely control the T-cell effector functions and sustain chronic inflammation in atherosclerotic disease.